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Background: Data on trends in breast cancer incidence and mortality in Puerto Rico are 
limited, as is information on therapeutic services available to women with breast cancer 
on the Island. Such data is necessary to evaluate the success of the recent expansion 
in health insurance coverage and public health efforts to increase breast cancer 
screening and reduce breast cancer mortality.  Expanding on reports from the Puerto 
Rico Central Cancer Registry (PRCCR), this dissertation analyzes breast cancer 
incidence and mortality trends in Puerto Rico for the period 2000-2013 by geographic 
health service region and clinical tumor characteristics, during which Medicare 
Advantage was introduced in Puerto Rico. It also evaluates therapeutic services 
provided over this period in one Medicare Advantage program.   
Methods: Breast cancer cases data was obtained from the PRCCR and population data 
from the Puerto Rican State Planning Board tables. A total of 20,228 females in whom 
invasive breast cancer was diagnosed during 2000 and 2013 were analyzed by age 
group, health service region, and clinical characteristics, including histological type, the 
grade of tumor, and disease stage at diagnosis.  Incidence rates were analyzed using 
Joinpoint analysis to study the trends during this period after age-adjusting to the female 
population of the United States. In addition, a utilization claims-based analysis was 
performed to document the frequency of medical and therapeutic services rendered in a 
Medicare Advantage Health Plan in Puerto Rico, MMM Holdings, from 2007 to 2016 
after the introduction of the Medicare Advantage Program.   
Results: Incidence rates significantly increased after 2007 with an Annual Percent 




100,000 females. Significant increases were found in rates of infiltrating duct cell 
carcinoma well and moderately differentiated tumors, in each stage of breast cancer.  
Mortality rates increased after 2007 with an Annual Percent Change of 2% (p-value = 
0.2), reaching a rate in 2014 of 25 per 100,000 females. Increases in mortality were 
explicitly observed in ductal cell carcinomas and for poorly differentiated and moderately 
differentiated tumors. Medical and pharmacy services increased for the female 
Medicare breast cancer population in Puerto Rico. A higher proportion of services and 
prescriptions, including injectable treatments, were rendered by physicians from their 
office setting during this time. 
Conclusion:  The introduction of the Medicare Advantage Program in Puerto Rico has 
impacted the ascertainment of more breast cancer cases and improved documentation 
of clinical characteristics of tumors. These findings enhance the understanding of breast 
cancer in Puerto Rico and guide efforts to improve medical care quality, especially 
among elderly females with breast cancer.  With this study methodology, we expect that 
describing breast cancer incidence and mortality rates by histological types, grade, and 
staging will become an integrated section in the reporting of future cancer publications 
in Puerto Rico.  Another recommendation is to increase the awareness among medical 
providers of the relevance of histological type, the grade of the tumor, and staging when 
evaluating the preventive services and treatment in breast cancer patients. A detailed 
evaluation of treatment episodes can be suggested as a next step, complementing the 









Studies of breast cancer in Puerto Rico are facilitated by the availability of data 
collected through the Census Bureau, Vital Statistic records, the Cancer Registry of 
Puerto Rico, and the CDC’s Behavioral Risk Factors Surveillance System.  Information 
concerning incidence and mortality rates is vital for creating awareness about the 
magnitude of the breast cancer burden in Puerto Rican women for health care providers 
and the population at large. However, publications describing rates by clinical 
classifications are scarce in Puerto Rico.  This dissertation addresses this matter, thus 
facilitating patient management quality, based on the 2014’s American Society of 
Clinical Oncology Guidelines for breast cancer.   
More specifically, this dissertation focuses on describing the increasing incidence 
and stable mortality among patients with malignant breast cancer in Puerto Rico, the 
first and second objectives.  We evaluated trends over time by age categories, 
geographical service region, histologic type, grading, and stage using data from the 
Puerto Rican Cancer Registry. Of particular interest was whether breast cancer patients 
were arriving late at diagnosis or with a higher prevalence of aggressive breast cancers, 
partly explaining the breast cancer mortality rates' stable behavior.  
Given that insurance paid claims information provides the opportunity to evaluate 
diagnostic and treatment modalities, this dissertation's third main objective was to 
describe the degree of medical and pharmaceutical treatment received in women with 
breast cancer in Puerto Rico.  Due to the absence of this information in the registry 




of this dissertation. This chapter's findings and recommendations will contribute to a 
better understanding of the disease and guide efforts to improve the quality of medical 
care, especially among elderly females with breast cancer in Puerto Rico. 
Dissertation Objective and Specific Aims 
 
Objective 
To describe the epidemiology of breast cancer incidence and mortality in PR women 
and treatment management of breast cancer in a segment of the population insured 
through Medicare.                                                                                                                                                                                                                                                                                              
Specific Aims 
The specific aims of this dissertation were: 
1. To describe the overall age-adjusted incidence and mortality rates for 
breast cancer in Puerto Rico women between 2000 and 2013, stratified 
by the Health Care Reform's geographical regions. 
2. To evaluate trends of incidence and mortality rates between 2000 and 
2013 by: 
a. Histologic types 
b. Tumor Grades and 
c. Stage at Diagnosis 
 
3. To describe the frequency of services and treatment modalities among 
breast cancer patients seen by the Castellana’s Medicare Advantage 





Background and Significance 
 
In the United States, Non-Hispanic Black and Hispanic women with breast 
cancer present with the most advanced stages compared to Non-Hispanic whites 
(American Cancer Society, 2020).  Puerto Ricans in the mainland of the United States 
are 20% to 50% more likely to have received or elected a first course of surgical and 
radiation treatment not meeting the National Comprehensive Cancer Network standards 
and have a 20% greater risk of mortality after a breast cancer diagnosis compared to 
Non-Hispanic whites (Li CI, Malone, 2013). 
On the island of Puerto Rico, the most recent state vital statistics report indicates 
that cancer was the second leading cause of death, with 5,008 cancer deaths occurring 
in 2008.  These deaths represent an age-adjusted death rate of 117.7 per 100,000 
inhabitants.  Despite the magnitude of overall 2008 cancer mortality in Puerto Rico 
being lower than in the United States (175.7), mortality is slightly higher than the 
mortality of 114.8 per 100,000 reported for 2009 in the USA’s Hispanic populations 
(American Cancer Society Report, 2012).  Among cancers in women on the Island, 
breast cancer is the first cause of death, followed by lung cancer (Department of Health 
of PR (DOH, Vital Statistics Report, 2010). 
These disparities in the US and PR cancer rates, especially breast cancer rates, 
are not clearly understood.  In Puerto Rico, significant efforts have been made to 
promote screening tests. Between 77% and 81% of women over 50 years have a 





Only a limited number of scientific publications on breast cancer in Puerto Rico 
have addressed these topics, to some extent, as a result of the lack of and delay in 
published cancer incidence and mortality data from the Department of Health and the 
State Cancer Registry.  The DOH is responsible for the publication of the annual vital 
statistics report.  The most recent one, published on September 16, 2019, on the DOH’s 
website, provides information on the state’s 2015 and 2016 mortality experience.  For 
this dissertation, the author was provided preliminary data through the year 2013 
following a written request for this data. Thus, the data presented below for the post-
2008 period were based on these preliminary data. 
Cancer incidence official reports are published bi-yearly on the Island by the 
Puerto Rico Central Cancer Registry (PRCCR).  Several gaps have occurred since 
SEER funding ended in 1989, and local funding only supported needed technology, 
personnel, and maintenance of physical facilities for this surveillance.   It was not until 
2001 that the PRCCR received continuous support from the CDC when generation and 
publishing responsibility were transferred to the Medical Sciences Campus.  The next 
report was published in 2010, describing the 2000 to 2004 data period, followed by the 
latest 2015 publication describing the 2008-2012 rates.   
For the first time in Puerto Rico, this dissertation conducted a population-based 
study using Medicare data from Health Insurance claims files of one of the most prominent 
Independent Practice Association called Castellana Physician Services.  We analyzed 
the distribution of breast cancer cases seen within the Castellana system by year and the 
related pharmaceutical and medical services utilization during the study period.  No study 




provided to breast cancer patients since the implementation of the Medicare Advantage 
program on the Island.  Analyzing these patterns will help evaluate the extent of breast 




While breast cancer rates are higher among women in more developed regions, 
rates are increasing in nearly every region globally (WHO, 2018). Breast cancer 
mortality rates have been decreasing in high-income countries, despite increasing or 
stable incidence rates.  The incidence of breast cancer has been increasing in the 
developing world due to increases in life expectancy, increased urbanization, and 
adoption of western lifestyles, and population adoption of screening (Nazario and 
colleagues, 2000). Early detection has been the primary public health strategy to 
improve survival and help control disease outcomes (WHO, 2018).  Although some risk 
reduction might be achieved with early detection through mammography screening, it 
cannot eliminate the majority of breast cancer deaths in low- and middle-income 
countries where breast cancer is diagnosed at late stages.  
A study using WHO data, found that 9 out of 32 countries with available data of 
incidence and mortality showed increasing incidence and reduction in mortality rates, 
mainly in Northern and Western Europe. Incidence and mortality have decreased in 
France, Israel, Italy, Norway, and Spain.   Incidence and mortality show an increase in 
Colombia, Ecuador, and Japan.  Only death rates have increased in Brazil, Egypt, 
Guatemala, Kuwait, Mexico, Mauritius, and Moldova (De Santis, 2015).  Also, incidence 




Japan, Singapore, and urban areas of China, as these regions transition toward a 
Western-style economy and patterns of reproductive behavior (Colditz, 2013). 
Puerto Rico 
Puerto Rico is a Caribbean Island, a territory of the United States of America with 
a total population of 3,725,789 based on the 2010 USA Census Bureau.  Women 
represent 52% of the population.  In 2010, there were 541,998 women older than 65 
years representing 14% of the population.  One out of every 11 women born will be 
diagnosed with cancer in their lifetime, with one-half of new cancer cases occurring in 
women aged 65 years and over (PRCCR, 2015). Recognizing the increasing cancer 
trends, public health officials in 1994 started a Health Reform initiative to increase 
access to services and reduce health disparities between the public and private 
healthcare sectors (DOH of PR, 2000, personal communication with Secretary of 
Health, Puerto Rico).  More prevention strategies were targeted to the public sector to 
reduce the number of new cancer cases in the population and address other health-
related conditions. 
Furthermore, in 2006, the Island’s Medicare population started receiving the 
benefits of the new Medicare Advantage (MA) program. By 2012, the Medicare 
Advantage program had succeeded in enrolling close to 80% of the Medicare 
population (Keyser, 2014).  MA private companies are now locally administering 
screening services provisions and supporting health care providers in cancer treatment 
modalities for most Medicare beneficiaries.  Data from the Behavioral Risk Factor 
Surveillance System suggests an improvement in breast cancer screening, as 
mammography prevalence increased from just 61% in 1996 to 79% in 2012 among 




Although MA coverage is now widely available across the Island, a higher 
prevalence of low socio-economic disparities exists among the senior population who 
have had scarce health resources for decades (Oficina Procuradora de la Vejez, PR 
2017).  The program will seek to enhance access to services by having Medicare 
members access close to 10,000 providers from multiple specialties who now all 
implement Medicare guidelines when servicing this population.  
Epidemiology of Breast Cancer in the USA and Puerto Rico 
 
Epidemiology of Breast Cancer in the USA 
Besides skin cancer, breast cancer is the most commonly diagnosed cancer among 
women in the United States, accounting for 250,520 new cases in 2017, or 
approximately 30% of all incident cancers (CDC, 2020).   About 1 in 8 U.S. women 
(about 12%) will develop invasive breast cancer throughout their lifetime (Breast Cancer 
Org. 2020 and CDC Website). https://www.cdc.gov/cancer/breast/statistics/index.htm. 
Regarding cancer deaths each year in the United States, about 42,170 women, 
or one in 39 women (3%), are expected to die of breast cancer, making it the second-
leading cause of cancer deaths among American women (Breast Cancer Org. 2020)   .   
Mortality rates have declined over the past 50 years, but since 2007, rates have 
remained steady (Breast Cancer Org, 2020). The lifetime risk of dying of breast cancer 
is approximately 3.4% (Colditz, 2013; and Breast Cancer Org, 2020).  These decreases 
are attributable to treatment advances, earlier detection through screening, and 




 Puerto Rico 
Breast cancer is the most commonly diagnosed cancer in Puerto Rican females 
and the second leading cause of death among females in Puerto Rico after cardiovascular 
diseases (DOH, Vital Statistics, 2010).  The adjusted incidence of breast cancer has risen 
more than six-fold over the past sixty years.  In 1950, fewer than 100 new cases of breast 
cancer were diagnosed in Puerto Rico.  The average age-adjusted incidence rate for the 
1950-1954 period was 12.8 per 100,000 females.  In 2010, 1904, breast cancer cases 
were diagnosed for an age-adjusted incidence rate of 77.6 per 100,000 females.   This 
represents a 506% increase in breast cancer risk (percent change) in 60 years.  Although 
screening rates in Puerto Rico are increasing, there is evidence of poor compliance in 
following mammography guidelines among providers that manage low income-middle 
age women (Sanchez, 2002). Failure to screen may contribute to advanced stages of 
breast cancer at the time of diagnosis, resulting in higher mortality rates. Patient 
characteristics and system delays in receiving treatment after diagnosis significantly 
contribute to the observed differential in survival in medically under-served or 
impoverished patients (Caplan, 2014). 
Breast Cancer Incidence 
As stated above, 1,904 new breast cancer cases were diagnosed in 2010 for a 
crude incidence rate of 98.2 per 100,000. The age-adjusted incidence rate was 77.6 per 
100,000 compared to 84.2 in the USA (Source, PRCCR as of August 2013).  Breast 
cancer accounted for 29.7% of all female cancers between 2006 and 2010.  Based on 
the incidence rates from 2006 to 2010, “8.6% of women born today will be diagnosed with 
cancer of the breast during their lifetime,” states the PRCCR report.  Between 1987 and 




while the “in-situ” breast cancer rates increased 8.5% a year, possibly explained by the 
increase in early detection efforts with screening mammography (PRCCR, 2013). 
Mortality 
During 2010, 5,197 deaths were reported on the Island.  Of these, 2,927 (56.3%) 
were among women.  Breast cancer accounted for 18.1% percent of all deaths in women 
in that year. A total of 411 deaths of breast cancer in 2010 accounted for a crude mortality 
rate of 21.1 per 100,000.  The age-adjusted rate was 15.9.  Mortality rates have 
decreased an average of 0.1% a year from 1987 to 2010 (PRCCR, 2013).  In 2008, the 
Vital Statistics Reports from the Department of Health reported 416 breast cancer deaths.  
The Cancer in Puerto Rico 2006-2010 report stated that an average of 412 women with 
breast cancer died from breast cancer each year during 2006 and 2010 for a crude death 
rate of 21.0 and an age-adjusted rate of 18.5 per 100,000 females adjusting for the USA 
population. 
Total cancer deaths and breast cancer deaths among females occurred most 
often among older women in Puerto Rico, as observed in the USA mainland.  Although 
rising slightly, breast cancer mortality rates remained lower in Puerto Rico than in the 
USA among all age groups.   
It’s important to highlight that breast cancer is the leading cause of cancer death 
among Hispanic women in the USA (American Cancer Society, 2014). From 2000 to 
2009, breast cancer death rates decreased by 1.6% per year among Hispanic women, 
and by 2% per year among non-Hispanic white women (American Cancer Society, 
2014).   
Even though progress has been made in reducing breast cancer mortality in 




the Island, and significant effort is needed to reduce the rate and reach state health 
objectives. 
Survival  
United States survival rates for breast cancer have increased slightly since the 
mid-seventies.  Data from 2019-2020 in the USA shows that survival rates in women 
diagnosed with breast cancer are 91% at five years after diagnosis, 84% after ten years, 
and 80% after 15 years (American Cancer Society, 2019).   
The overall relative five-year survival rates for 2009-2015 were 92% in Whites 
versus 83% in Blacks over the same period.  Some of the possible reasons for better 
survival in Whites are that Whites seek medical attention earlier than Blacks (Oii and 
colleagues, 2011).  First, the time between symptoms and presentation seems to 
account for differences in survival rate or diagnosis stage.  Secondly, less aggressive 
modes of treatment are used for Black than Whites.  Third, a higher proportion of poorly 
differentiated tumors are found among Blacks who often have a poorer nutritional 
status, including high relative weight (Oii and colleagues, 2011).  In contrast, White and 
Hispanic survival rates are similar, independent of the stage of disease and difference in 
tumor histology (Oii and colleagues, 2011). 
Breast Cancer Survival in Puerto Rico 
 
Only one study evaluated breast cancer survival in Puerto Rico, a hospital-based 
study in the Oncologic Hospital of Puerto Rico (Ortiz et al., 2013).  Among patients with 
localized stage, women with Triple Negative (TN) breast cancer had a higher risk of 
death (adjusted hazard ratio [HR]: 2.57, 95% confidence interval [CI]: 1.29–5.12) as 




al., 2013). Among women with regional/distant stage at diagnosis, those with TN breast 
cancer (HR: 5.48, 95% CI: 2.63–11.47) and those with HER-2+, including HER-2 
overexpressed and Luminal-B, (HR: 2.73, 95% CI: 1.30–5.75) had higher mortality. 
(Ortiz et al., 2013).  
Histogenesis of Breast Cancer 
 
To improve breast cancer patients' prognosis and avoid treatment failure, it is 
essential to understand the relationship between pathologic tumor characteristics such 
as histologic class, nuclear grade, and disease staging.  Pathologists classify tumor 
cells by cell growth and their microscopic features to classify them on aggressiveness 
and the potential to metastasize.   There are four types of prognosis categories 
according to histologic types (Rosa,1981): 
Type I (Noninvasive):   
Ductal Carcinoma NOS  
Lobular carcinoma in situ (LCIS-lobular neoplasia) 
 
Type II (Invasive, circumscribed margins, rare metastasis):  
Pure mucinous carcinoma    
Tubular Carcinoma   
Invasive Papillary Carcinoma   
Medullary Carcinoma    
 
Type III (Invasive, moderately metastasizing):  
 Invasive ductal carcinoma NOS  
 Intraductal carcinoma with invasion  
 Invasive lobular carcinoma  
 
Type IV (Invasive, undifferentiated carcinoma): 
 Tumors indisputably invading blood vessels regardless of the type 
 
The relative proportions of each tumor type have been estimated in various 




majority are adenocarcinomas, of which most are classified as infiltrating ductal cell 
carcinomas.  Slight variation is seen among different ethnic groups, with medullary 
carcinomas occurring more frequently in Hispanic, Black, and Chinese women than in 
white women (Kelsey, 1993; Li, 1993).  All the above histologic subgroups can exist in 
combination with ductal carcinomas NOS; coexistence has been estimated to occur in 
some 17% to 30% of cases.   
  
Tumor Grade 
A well-known quotation summarizes the importance of tumor grade: “The more 
atypical the structure, the better the prognosis” (Ashikari, et al, 1974).  The tumor grade 
is a score that tells us how pathologically different the tumor cells are from a normal and 
healthy breast cell.  The correlation between the microscopic differentiation of tumors 
and the tumor’s clinical behavior was first observed by Duncan (quoted in 
Azzopardi,1979).  Bloom and Richardson used the pattern of tubular arrangement, the 
nuclear pleomorphism, hyperchromasia, mitotic ratio, and axillary lymph node status to 
independently assess a grading category (Bloom and Richardson, 1957):  
● Well-differentiated (Grade 1 or low grade),     
● Moderately differentiated (Grade 2 or intermediate grade),    
● Poorly differentiated (Grade 3 or high grade) and    
● Undifferentiated (Grade 4 high grade). 
 
This gradient of aggressiveness is also found within these breast cancer subtypes. The 





 Staging at Diagnosis 
The stage of the disease has been identified as an important predictor of patient 
survival. Staging refers to the classification of breast cancer by its anatomical extension.  
The rationale is that cancers progressively extend, and progression is related to 
prognosis (Donegan, 1995).  Staging facilitates treatment selection and comparison of 
treatments across similar cases. The USA SEER Cancer Registry structures stages in 
the following categories:   
o In situ  
o Localized  
o Regional by direct extension only  
o Regional lymph nodes only  
o Regional by BOTH direct extension AND lymph node involvement 
o Distant site(s)/node(s) involved.  
o Benign/borderline 
o Unknown if extension or metastasis (un-staged, unknown, or unspecified)  
 
Using this gradient of aggressiveness facilitates understanding the distribution of 
these breast cancer subtypes, focusing on higher grades with faster and more 
disorganized growth in new cancer cells.  Based on the SEER database, the American 
Cancer Society reported that the USA’s 5-yr survival rates were 99% for localized 
tumors, 86% for regionalized, 27% for distant tumors, and all stages combined 90% 
(American Cancer Society, 2020).  However, the 5-yr survival rates are not stratified 
systematically by the SEER registry.  Historically, a 1971 study reported a 5-yr survival 
rate of 81% among breast cancer patients with Grade I, 50% percent among patients 
with Grade II, and 35% among patients with Grade III (Bloom, 1971).   In more recent 
years, the research has identified the benefits of linking the information of grade of the 
tumor and the patients’ stage at diagnosis, which can better predict the survival 




Medical Care Access in Puerto Rico 
In the 1970s, Puerto Rico’s government-funded public health system began to 
weaken while the private sector began to grow (Arbona and Ramírez de Arellano, 
1978). The public health system became increasingly decentralized and fragmented.  
Early evaluation of Puerto Rico’s Medicaid program showed that approximately 12 
percent of participating physicians billed for 43 percent of all Medicaid visits (Arbona 
and Ramírez de Arellano 1978). Access to health services in Puerto Rico changed 
significantly starting in 1994 when the Government established a Health Reform giving 
health insurance companies an essential role in administering health service provisions 
to the medically indigent population.  By 2000, the Medicare Advantage program had 
successfully penetrated close to 80% of the Medicare population. These Advantage 
companies were locally administering screening services and supporting health care 
providers in cancer treatment modalities for most of the Medicare Population.  This 
dissertation analyzes the incidence and mortality rates by service region.   
Methods 
Overview 
For Aim 1 and 2, we obtained de-identified data from all breast cancer cases 
from the Puerto Rico Central Cancer Registry (PRCCR) from 2000 to 2013.  The 
information included age, gender, the township of residence at the time of diagnosis, 
and the following clinical characteristics: stage at diagnosis, histology, and tumor grade. 
Date of diagnosis and information on vital status, including death date for deceased 
cases, were also obtained.  Information on the population size and age structure of the 




 The Puerto Rico government has designated eight service health regions 
recognized by the health plans that serve the indigent population. Age-adjusted 
incidence and mortality were calculated overall and by these services regions to provide 
a more familiar geographical analysis for government and private companies 
administering services to the population. Lastly, incidence and mortality trends were 
stratified and analyzed by histologic type, tumor grade, and stage at diagnosis.  
Registry Study 
In Part I, we used de-identified data provided by the Cancer Registry.  The Data 
was requested from the PRCCR using their standard protocol forms “APPLICATION TO 
ACCESS PRCCR DATA” (see Appendix 1 & 2). The request was considered Level II, 
which stands for “Data files containing individual, record-level data with personal 
identifiers, to be used for purposes of record linkage, either electronic or manual, but not 
direct patient contact. Once the record linkage was complete, the personal identifiers 
were removed from the data set.  The following variables were obtained from the 
PRCCR: Patient Sex, Age at Diagnosis, Cancer type, Date of diagnosis, Date at death, 
Township of Residence, and the following disease clinical characteristics: Stage at 
diagnosis, Histologic Type, and Grade of the tumor. 
The Puerto Rico population census estimates and specific female estimates by 
municipality were downloaded from the Census Publicly available files in the USA 
Census website: https://www.census.gov/popest/data/datasets.html. Population 
estimates from the State Planning Board public available files by municipality for the 
2000 data files were used to generate regional and total population for the Island by 




Incidence and mortality rates were generated using information from new cases 
from the Cancer Registry over the population estimates obtained from the Planning 
Board [Junta de Planificación]. Cancer Registry data were weighted with USA Census 
population estimates for Puerto Rico to standardize rates and make them comparable to 
the USA rates. Annual age-adjusted incidence and mortality rates adjusted to the USA 
2000 population were calculated using counts from the PRCCR data and population 
size based on the US census, for all cases and by clinical characteristics for the whole 
island and by health region using SAS 9.4. Trends for the Island as a whole and each 
health region were graphed over time to assess temporal trends using NCI's Joinpoint 
Regression Program (Version 4.1.0). 
Services and Treatment Modalities in breast cancer 
This dissertation's third aim was to perform a ten-year utilization profile of 
Medicare breast cancer patients in Puerto Rico.  To achieve this, we analyzed breast 
cancer patients in Puerto Rico.  We analyzed patient characteristics and their related 
pharmaceutical and medical services utilization from 2007 to 2016. 
To address this aim, demographic, medical, and pharmacy claims files were 
analyzed for a Medicare Advantage Independent Practice Associations (IPA) in Puerto 
Rico called Castellana Physician Services (see Appendix 2 & 3).   Castellana is an 
Independent Physician Network of almost 400 Primary Care Physicians in Puerto Rico.  
The Provider’s groups are mainly General Practitioners with specialties in General 
Medicine, Family Medicine, and Internal Medicine.  The providers are grouped into four 
Regions of the Island: Northeast, East, Metronorth, and Southeast.  These providers 




Advantage Health Plans on the Island (MMM and PMC Medicare Choice).   The 
Castellana Central Office provides administrative support to each of the 400 providers, 
with a group of Regional Medical Directors and the nursing and administrative staff 
facilitating the communication with the Health Plan’s administration.  For January 2014, 
Castellana’s membership consisted of 55,219 active members distributed in four Island 
regions, of which approximately 30,000 were female members.  Each of the members 
received services from these Primary Physicians and used the Health Plan Contracted 
Specialists and/or other Providers’ Networks to obtain additional clinical services. 
Findings in this study population thus likely represent the best healthcare standards in 
Puerto Rico for the elderly population. 
This is the first study of claims data using an IPA specific Medicare population 
from the only NCQA certified Health Plans in Puerto Rico (MMM and PMC).  Castellana 
served MMM and PMC exclusively, and Castellana’s population represents a significant 
segment of the market and the biggest IPA. The study's findings apply to the Health 
Reform Regional distribution, which the government uses to allocate the funding for 
state funds for health insurance companies.  Health plans and government decision-
makers will be able to use the results as benchmarks for future surveillance.  
Chapter II presents breast cancer incidence and mortality trends by geographic 
region. Chapter III presents the trends by the clinical characteristics of the disease. 
Chapter IV presents the analysis of the Castellana claims data. Chapter V discusses the 
main findings, discusses the policy implications of these findings, and makes 
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Age-adjusted incidence and mortality rates for malignant breast cancer in Puerto Rico 
between 2000 and 2013, stratified by geographical regions of the Health Care Reform 
Introduction 
Breast cancer incidence in Puerto Rico has been significantly increasing by 1.5% 
during the period of 1987 to the year 2012, while for the same period, mortality 
decreased by 0.1% a year (Zavala 2015).  Cancer in Puerto Rico 2008-2012, the most 
recent published report, states that breast cancer is the most commonly diagnosed 
cancer among females with an average of 1,971 new malignant cases every year.  
Breast cancer accounted for 29.6% of all cancers in women and 19% of all cancer 
deaths, with an average of 423 deaths per year.  Similarly, an independent study on 
patterns of lifetime risks on breast cancer reported that the age-adjusted breast cancer 
incidence rate (per 100,000) in Puerto Rico increased from 15.3 in 1960-1964 to 43.3 in 
1985-1989. The age-adjusted breast cancer mortality rate (per 100,000) increased from 
5.7 to 10.6, comparing the same two time periods (Nazario, 2000). Despite the 
government’s and private health insurance companies' efforts to promote awareness of 
early detection and availability of screening and treatment options among different 
stages of diagnosis, the number of breast cancer cases has been increasing with a 
minimal effect on the reduction of breast cancer deaths in the Island. 
Puerto Rico (PR), a territorial Caribbean island of the United States of America, has 
a total population of 3,725,789 based on the 2010 USA Census Bureau (USA Census 
2010). Women represent 52% of the population.  In 2010, 305,577 women were older 




group in 2010 increased by 31% compared to the 2000 Census (US Census 2010).  
Based on the most recent published data from the Puerto Rico Central Cancer Registry 
(PRCCR), 1 out of every 11 women born will be diagnosed with cancer in their lifetime, 
with one-half of new cancer cases occurring in women aged 65 years and over. 
Recognizing the increasing cancer trends, public health officials needed a new 
prevention strategy to reduce the number of new cancer cases in the population and 
address other health-related conditions. 
The health system in Puerto Rico consists of two components.  On one side, private 
hospitals, pharmacies, and local providers offer a fee-for-service model.  In parallel, the 
public sector -- with public hospitals, emergency centers, clinics, and secondary and 
tertiary hospitals that provide free service across the Island -- serves the poverty-level 
indigent population. The government's substantial cost, high levels of bureaucracy, and 
complaints of long waits for specialty services contribute to dissatisfaction with the 
public health system (DOH, Title V Block Grant, 2017). 
In 1994, PR started a Health Reform initiative, which refers to the territory’s Medicaid 
plan that is a subset of the larger governmental healthcare delivery system, as a 
strategy to increase access to services and to reduce health disparities, such as infant 
mortality rates, between the public and private healthcare sectors. For example, the 
infant mortality for the Puerto Rico birth cohorts 1986/1987 through 1989/1990 for the 
public sector was 16.5 per 1,000 live births as compared to 7.5 per 1,000 live births for 
the private sector (Becerra,1993). The Health Reform initiative had three objectives:  (1) 
reduce PR’s healthcare footprint by selling tertiary and secondary health facilities to the 




strategies for healthy lifestyles and early cancer detection and treatment; and (3) 
delegate the administration and managed care activities to the private sector under the 
oversight of a new government agency called “Administración de Seguros de Salud” 
(ASES) (DOH-Title V Block Grant, 2017) 
Briefly, the Health Reform initiative started its implementation in 1994 in the east 
region and concluded in 2000 in the San Juan Region (Figure 2.1). The government 
grouped Puerto Rico’s 78 municipalities into ten (10) service regions. Each region was 
assigned to a different health insurance company to increase competition, improve 
access to care, control costs, and avoid monopolizing the services within the Island. 
In 2006, the new Medicare Advantage (MA) program arrived on the Island. By 
2012, the Medicare Advantage program had succeeded in enrolling close to 80% of the 
Medicare population, a total of 483,978 individuals (Henry Keyser Foundation, 2014).  
These MA private companies are now locally administering screening services provision 
and supporting health care providers in cancer treatment modalities for most of the 
Medicare beneficiaries.   
Although MA coverage is widely available across the entire Island, 
socioeconomic disparities among this senior population persist in some geographical 
regions, for example in the Southeast region.  Politicians and community leaders have 
called the Southeast region the “Ruta del Hambre” (i.e., the Hunger Route), given that 
the government and private sector have not invested in this area for decades (“El nuevo 




Puerto Rico Cancer Registry  
The Puerto Rico Cancer Registry was established in 1951 and is one of the 
oldest cancer registries in Latin America (Tortolero-Luna 2013). It attained many 
achievements, including becoming part of the U.S. Surveillance, Epidemiology, and End 
Results (SEER) Program from 1973 to 1989.  However, in 1989, the registry lost its 
SEER membership due to its inability to keep up with the SEER’s technology 
requirements.  From 1989 to 1997, the registry operated with limited government funds, 
resulting in sparse publications of statistical reports. It was not until 2001 that the new 
Puerto Rico Central Cancer Registry (PRCCR), under the University of Puerto Rico 
Medical Sciences Campus administration, began receiving continuous support from the 
U.S. Centers for Disease Control and Prevention (CDC) for systematic operation.  In 
2012 PRCCR started bi-annual publishing reports with crude 5-year cancer incidence 
rates for PR and its 78 municipalities (Figure 2.1). 
Studies of breast cancer in Puerto Rico are facilitated by the availability of data 
collected through the Census Bureau, the vital statistics records, and the PRCCR.  
Information concerning incidence and mortality rates is essential for creating awareness 
about the magnitude of the breast cancer burden among Puerto Rican women and 
health care providers at large. This paper describes the malignant breast cancer 
incidence rates and mortality rates for the period of 2000 to 2013, overall and by health 
insurance regions.  Stratifying rates by health insurance regions presents a novel 
approach that may improve how public health stakeholders identify areas to prioritize for 
services and education.  Further, we investigate whether the geographical distributions 




were allocated with differential access to health services between 2000 and 2013.  This 
paper aims to expand the breast cancer incidence and mortality information so that local 
health administrators can evaluate the efficacy of their prevention efforts both in the 
government and private health sector. The study hopes to understand better how 
funding allocations could impact the rate of cancer incidence and mortality and improve 
PR women's health outcomes with breast cancer.  We expect to observe higher 
incidence rates of breast cancer. Still, declining mortality had increased awareness in 
preventive screening in the Medicare Advantage Populations, especially after 2006, 
when Medicare Advantage started on the Island. 
Methods 
Data Source and Data Management 
 
For this analysis, PRCCR supplied a data file containing the information 
necessary to study a total of 29,750 breast cancer cases from 2000 to 2013. The 
variables provided for each case included: encrypted case number, diagnosis date, last 
contact date, gender, age at diagnosis, diagnostic city, primary site, histologic type, 
grade, SEER Staging, vital status, and cause of death diagnostic code. 
Incidence Trend Analysis 
Overall crude rates were electronically computed using the total frequencies of 
new breast cancer cases over the entire female population.  Next, we calculated the 
regional rates using the total numbers of new breast cancer cases by region over the 
female population estimates by age group and municipality of residence from the State 




rates were calculated using the U.S. 2000 Census female population estimates by age 
group as the standard population to control the aging population.     Age-adjusted 
incidence rates for PR females from 2000 to 2013 using the U.S. Census 2000 
Standard Population were calculated (PR Census Profile, 2010).  Cancer incidence 
rates were then analyzed in the Joinpoint Regression Program (National Cancer 
Institute, 2020).  Joinpoint regression allows for breaking the incidence trends into time 
segments to identify years in which there was a statistically significant change in trend 
("joinpoints"). For each time segment, the analysis estimates the annual percentage 
change (APC) in the incidence/mortality rates during that period and determines 
whether the APC is statistically different from zero (no trend) at an alpha level equal to 
0.05. 
Recoding and Categorization 
Recoding and categorization of the PRCCR data were done using the SAS 9.4 
software.  The variables that required recoding were: “year of diagnosis,” “age 
categories,” “primary tumor site,” “patient vital status,” “health region,” and “gender.”  A 
key variable that was defined for the mortality analytical purposes was the “year of 
death” based on the “last seen date” information.  
The inclusion criteria were established in the following order:  only females, 
breast cancer as the primary diagnosis, Puerto Rico residents, known age at diagnosis, 
no in-situ diagnosis, and non-borderline status.  A total of 9,522 did not meet the 
selection criteria for a final study population of 20,228 cases with malignant breast 




The following groups were excluded: 
● 260 males 
● 5,783 breast cancer cases with more than one primary site to limit breast cancer 
selection only and breast cancer as the primary malignancy.  
● One case living outside of Puerto Rico.  
● 25 cases with unknown age at diagnosis.   
● 38 SEER breast cancer cases were excluded given Hodgkin and Non-Hodgkin 
Lymphomas of All Sites not related to breast cancer diagnostics based on the 
SEER breast cancer criteria for histologic codes: 9590, 9596-9663, 9673-9679, 
9687-9698, 9716-9719, 9725-9726, 9735, 9737-9738.  
https://staging.seer.cancer.gov/eod_public/schema/1.1/lymphoma/ 
● 3,405 in situ cases 
● One case with a tumor morphology in a Borderline status.  
Results 
Table 2.1 summarizes the total counts of breast cancer patients by health service 
region and presents the start year for the health care reform regions.  Female 
population estimates by region are listed, and the 2000- and 2013-years incidence rates 
and increment percent by region are displayed. Annual percent change adjusted death 
rates, and percent increases are also demonstrated in this summary table.  The San 
Juan and North West regions of the Island showed the highest breast cancer incidence 
rates for 2013.  The South East, the Northwest, and the East regions presented the 




the San Juan Region presented the highest age-adjusted death rates on the Island.  
The Northwest, the Central, and Northeast showed the highest increase compared to 
the year 2000 death rates. 
 
Incidence of Malignant Breast Cancer in Puerto Rico 
Our results show that Puerto Rico incidence rates were lower than the U.S. rates 
and the U.S. Hispanic rates for the study period (Figure 2.2).  The malignant breast 
cancer incidence age-adjusted rates for Puerto Rico increased from 70 cases per 
100,000 females in 2010 to 81 cases per 100,000 females in 2013.  The rates remained 
lower than the overall U.S. rate but approached rates in the U.S. Hispanic population.  
Joinpoint analysis 
The age-adjusted malignant breast cancer incidence rate increased from 63.04 in 2000 
to 81.03 cases per 100,000 person-years in 2013, at an average annual percent change 
of 2.1 per year. The Joinpoint analysis (Figure 2.3) showed that in the first part of the 
period, 2000 to 2006, there was a small and non-significant annual percent change in 
the incidence rates (APC= 0.08%; p-value 0.8616).  The incidence started to increase in 
the year 2006 and showed a high and statistically significant annual percent change of 
3.63 for the period 2007 to 2013 (p-value <0.00016).    
 
Breast Cancer Incidence Rates for Females by Age Categories 
 
Incidence rates increased for all-female groups under 40 years of age, 40 to 59 
years of age, and 60 years of age or older in the study period. However, there are some 




rates for women under 40 years of age (Figure 2.4, Table 2.3) consistently increased 
and almost doubled for the period.  The rates increased from 6.63 in 2000 to 12.31 
cases per 100,000 person-years in 2013, representing a statistically significant 3.2% 
annual percent change (APC) for the period (p-value <0.0273). 
For the PR female group 40 to 59 years of age, the adjusted breast cancer 
incidence rate increased from 111.61 in 2000 to 145.24 cases per 100,000 person-
years in 2013 (Figure 2.5).  A non-significant increment in the incidence was observed 
for this age group during the 2000 to 2007 period with an APC of 0.01% (p-value of 
0.9945). However, starting around 2007, the incidence began to increase at a 
statistically significant APC of 4.22% (p-value<0.0217).  
Finally, the age-adjusted breast cancer incidence rates for women over 60 years 
of age increased from 184.7 in 2000 to 229.6 cases per 100,000 person-years in 2013 
(Figure 6).  The Joinpoint analysis showed a non-significant reduction in the rates for 
the first part of the period from 2000 to 2003 (APC= -3.61%). However, there was a 
statistically significant increase in the rates for the remaining portion of the period 2003 
to 2013 with an (APC=3.35%; p-value of 0.026) (see Figure 2.6). 
Breast Cancer Incidence Rates by Health Service Regions    
 
We next analyzed the age-adjusted incidence rates for the 2000-2013 period by 
the ten Health Reform geographical regions.  The presentation order of these sections 
below is based on the magnitude of the rates, not the order in which the regions entered 
the government health reform.   
The age-adjusted breast cancer incidence rates for the San Juan region show a 




reduction of almost 7% per year (APC= -6.84; p-value<0.0429) (Figure 2.7). Starting in 
2004, an increase in the incidence rates was observed for the remainder of the period 
with a statistically significant annual percent change of close to 2% (APC=2.18% p-
value<0.0349). The incidence rate for the year 2000 was 97.8, and the rate for the year 
2013 was 91.4.   
The North-Metro region presented the highest incidence rate on the Island (Figure 
2.8). The analysis shows a non-significant decrease for the period 2000 to 2013, with an 
annual percent change of almost 1% (APC=0.92; p-value of .2270).  The incidence rate 
for the year 2000 was 102.4, and the rate for the year 2013 was 100.8.   
The Northeast region age-adjusted incidence showed a significant statistical 
increase o for the period, with an annual percent change of 2.71 per year (p-value of 
0.0004) (Figure 2.9). The incidence rate for the year 2000 was 71.5, and the rate for the 
year 2013 was 89.96.    
The age-adjusted incidence rates in the North region presented a statistically 
significant increase for the period of 2000 to 2013 with an annual percent change of nearly 
4% per year (APC= 3.78; p-value < 0.000011) (Figure 2.10).  The rate in the year 2000 
was 57.1 cases per 100,000 persons and 84.2 cases per 100,000 person-years in 2013. 
The East region age-adjusted incidence rates presented a statistically significant 
increase for the period with an annual percent change of just over 4% per year 
(APC=4.32%; p-value of 0.000012).  (Figure 2.11).  The rate in the year 2000 was 50.2 
cases per 100,000 persons and 92.5 cases per 100,000 person-years in 2013.   
Similarly, the Central region age-adjusted incidence rates showed a significant 




4% per year (APC=3.89; p-value of 0.000065) (Figure 2.12).  The rate for the year 2000 
was 42.8 in 2000 to 65.4 cases per 100,000 person-years in 2013. 
In the Southeast region, the age-adjusted incidence rates presented a 
statistically significant increase for the year 2000 to 2013 with a 6% annual percent 
change per year (APC= 6.02; (p-value of 0.000016) (Figure 2.13).  The rate for the year 
2000 was 17.5 in 2000 to 48.3 cases per 100,000 person-years in 2013. 
The Northwest region age-adjusted incidence rate showed a non-statistically 
significant increase with an annual percent change of slightly over 2% per year 
(APC=2.36; (p-value of 0.0931) (Figure 2.14). The rate for the year 2000 was 36.7 in 
2000 to 58.4 cases per 100,000 person-years in 2013. 
The Southwest Region’s age-adjusted incidence presented a statistically 
significant increase in the annual percent change close to 2% per year (APC=2.26; (p-
value of 0.00021) (Figure 2.15).  The rate for the year 2000 was in 2000 to 54.4 cases 
per 100,000 person-years in 2013. The West Region age-adjusted breast cancer 
incidence rates were stable during the years 2000 to 2013.  The annual percent change 
was not statistically significant and close to zero (APC-0.03; p-value of 0.94) (Figure 
2.16). The rate for the year 2000 was 37.5 2000 and 41.32 cases per 100,000 person-
years in 2013.  The rates for cases with an unknown residence or unknown region 
showed a statistically significant reduction in the age-adjusted incidence rates for the 
2000 to 2013 period with a negative annual percent change close to 11% (APC = –
10.90 per year; p-value of 0.0004) (Figure 2.17).  A summary of the annual percent 
changes, incidence rates, and volume of cases is detailed in Table 2.1 to better inform 





Out of the total of 20,228 patients from the PRCCR Data, a total of 5,764 had 
died as of the date that the data was provided. Out of the 5,764 deaths, a total of 3,790 
(65.3%) were caused by breast cancer based on the diagnostic codes.  The total and 
adjusted death rates by age are described in Figure 2.18 and Table 2.2.  The mortality 
rate trend for Puerto Rico was higher than the overall U.S. breast cancer rate as well as 
higher than the U.S. Hispanic rate for the 2007 to 2014 study period (U.S. rates source:  
SEER Registry data) 
Mortality by Geographical Regions   
 
Mortality was evaluated by the member residence's geographical location based 
on geographical areas defined by the government entity responsible for the managed 
care of the Medicaid population.  A total of 3,472 breast cancer deaths were reviewed 
for the study period. Regarding total deaths counts, the San Juan region and the East 
region had more deaths, and the Southeast and the West presented a lower number of 
deaths (Figure 2.19). 
 To control for the effect of demographic changes, mortality rates adjusted by age 
were calculated. Figure 2.20 presents the age-adjusted mortality rates by Health 
Reform Region by year. For the geographical distribution of mortality rates, the West 
and the Southwest showed an increase in the study period.  The West's mortality rate 
presented a spike in 2012 compared to the rates of the other regions see Figure 2.20. 
 The regions with the highest death rates were the West Region, with an adjusted 
death rate of 25.11, followed by the San Juan Region with a death rate of 21.36 for the 




year 2007 were the Northwest and Central Regions. Joinpoint regression analysis was 
not performed to evaluate trends in mortality rates by regions given the relatively small 
number of deaths reported each year in each region and the lack of information on 
death information for the beginning of the period. 
Discussion 
This study describes an observed change in the incidence trend starting in 2007, 
suggesting a possible impact of the Medicare Advantage Program on the breast cancer 
diagnosis in Puerto Rico.  This central finding was observed when analyzing the 
incidence rates for malignant breast cancer and mortality rates stratified by Health 
Reform Region for 2000 to 2013. We investigated whether the geographical 
distributions of breast cancer cases and deaths across regions defined by the new 
Health Reform and documented that the incidence and death patterns varied by region.  
Such differences may reflect how funds were allocated or differential access to health 
services between 2000 and 2013.  
The first goal of the study was accomplished when we described the trends in 
incidence rates for Puerto Rico between the years 2000 to 2013.  The increase in the 
incidence rate observed starting around the year 2006 suggests an impact of the federal 
Medicare Advantage (MA) program, which began in 2006.  The population that enrolled 
in a MA plan was able to receive, from their primary care physicians, more referrals for 
preventive services, earlier referrals to specialists, and diagnostic testing and early 
treatment options now paid by the program. Given that more diagnostic testing was 
done to screen the female population better, faster documentation of cases resulted in 




might be related to the Health Reform initiative and increased MA coverage penetration 
among PR beneficiaries since 2007.  Notably, although incidence rates were lower in 
Puerto Rican women than in US women or US Hispanic women, mortality rates were 
higher, with increases in mortality observed through 2012. Improvements in the health 
services access model allowed Puerto Rican females to receive earlier breast cancer 
screening, earlier diagnostic testing, and access to treatment, which might account for 
the observed decrease in breast cancer mortality after 2011. 
The Southeast region observed the most remarkable percentage change in its 
incidence, and one of the lowest increases in mortality among the regions.  The 
Southwest region deserves more study given its elevated mortality rates figures, 
Like all ecological analyses of population-level data, this study is subject to 
several limitations. First, given the ecological nature of the analysis, no conclusions can 
draw regarding causal factors behind the observed trends not having the information on 
the type of health insurance, e.g., Medicare, Medicaid, Commercial types, within the 
registry data limited the analysis options for the specific source of the funding program.  
Efforts to obtain and document the insurance type in the registry will enhance future 
studies' analytical opportunities.  Potential bias, common to cancer registry-related 
studies, might have occurred if local health providers reported incomplete case 
ascertainment and/or not all Cancer Registry cases.  Significant efforts to improve 
breast cancer surveillance obtaining information on new cases activity reported to the 
health insurance companies could complement the cases reported to the Cancer 




for local health and state administrators to better coordinate early treatment efforts both 
in the government and private health industry. 
The data presented here suggest that implementing these reforms from the state 
and federal governments resulted in earlier diagnosis, which may increase the 
incidence and the observed declines in mortality rates in the Island for the study period. 
The Joinpoint analysis conducted in this study demonstrates that the increase in 
malignant breast cancer presented during the year 2000 to 2017 started specifically 
around 2007 when the Medicare Advantage Program became available on the island, 
which this author will expound on in Chapter III.  
 All service regions presented increases in the incidence rates, especially the 
South East, East, and Central regions (Table 2.3). The highest increment in incidence 
was observed in the 65-year-old female population, and mortality age-adjusted rates 
increased from 2007 to 2013 in all service regions.  The most evident accomplishment 
of the government Health Reform and the Medicare Advantage Program was to provide 
more access to services.  This resulted in better and faster documentation of new cases 
in the health service regions.  This translates to earlier treatment, reducing early 
mortality in more aggressive types of tumors, especially among patients in advanced 
stages of the disease unaware of their diagnosis, which will be expounded in Chapter 
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2007-2013 APC = 3.63^
^ The Anual Percent Change (APC) is significantly different from zero at alpha level = 0.05









































































































^ The Anual Percent Change (APC) is significantly different from zero at alpha level = 0.05
Final Selected Model: 0 Joinpoints.
Figure 2.3 Puerto Rico Malignant Breast Cancer Age-Adj Rates 
 
 















































































































2007-2013 APC = 4.22^
^ The Anual Percent Change (APC) is significantly different from zero at alpha level = 0.05











































































































2003-2013 APC = 3.35^
^ The Anual Percent Change (APC) is significantly different from zero at alpha level = 0.05
Final Selected Model: 1 Joinpoint.
Figure 2.5 Malignant Breast Cancer Age-Adj Rates for females 40-59 years 
 





















































































































2004-2013 APC = 2.18^
^ The Anual Percent Change (APC) is significantly different from zero at alpha level = 0.05
Final Selected Model: 1 Joinpoint.
Figure 2.7 Malignant Breast Cancer Age-Adj Rates in the San Juan Region 
 
 











































































































^ The Anual Percent Change (APC) is significantly different from zero at alpha level = 0.05







































































































































^ The Anual Percent Change (APC) is significantly different from zero at alpha level = 0.05






































































































^ The Anual Percent Change (APC) is significantly different from zero at alpha level = 0.05
Final Selected Model: 0 Joinpoints.

























































































































^ The Anual Percent Change (APC) is significantly different from zero at alpha level = 0.05






































































































^ The Anual Percent Change (APC) is significantly different from zero at alpha level = 0.05
Final Selected Model: 0 Joinpoints.















Figure 2.13 Malignant Breast Cancer Age-Adj Rates in the Southeast Region 









































































































^ The Anual Percent Change (APC) is significantly different from zero at alpha level = 0.05










































































































^ The Anual Percent Change (APC) is significantly different from zero at alpha level = 0.05





Figure 2.15 Malignant Breast Cancer Age-Adj Rates in the Southwest Region 












































































































^ The Anual Percent Change (APC) is significantly different from zero at alpha level = 0.05






































































































^ The Anual Percent Change (APC) is significantly different from zero at alpha level = 0.05

























Figure 2.17 Malignant Breast Cancer Age-Adj Rates with Unknown Region 





































































































^ The Anual Percent Change (APC) is significantly different from zero at alpha level = 0.05
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Table 2.1 Summary Table Incidence and Mortality Rates for Puerto Rico Malignant Breast Cancer 





































1039 1994 122,016 31.2 102.5 71.3 5.9* 11.54 13.42 1.88 
East 2101 1996 225,291 50 105.5 55.5 4.6* 14.05 16.68 2.63 
North 2326 1995 234,959 52 91 39 3.9* 13.53 13.18 -0.35 
Central 1764 1995 224,675 42.1 75 32.9 3.9* 7.15 14.55 7.4 
North 
East 
2598 1994 245,259 61 98 37 2.8* 12.52 19.89 7.37 
San 
Juan 
2717 2000 213,694 89.9 116.7 26.8 2.4* 16.72 21.36 4.64 
North 
West 
1421 1996 141,085 54.1 111.04 56.94 2.4* 11.72 19.05 7.52 
South 
West 




2916 1998 263,267 81.6 99.6 18 0.9 12.77 16.2 3.43 
West 1388 1998 107,629 74.1 105.3 31.2 0.01 21.96 25.11 3.15 
 




Table 2.2 Breast cancer mortality rates per 100,000 females 
 2007 2008 2009 2010 2011 2012 2013 2014 
PR crude mortality rate 21.74 24.62 25.06 25.84 27.72 29.44 28.99 27.79 
PR age adjusted mortality 
rate 21.22 23.62 23.41 24.04 25.58 26.85 25.95 24.75 
U.S. age-adjusted 
mortality rate 
23.00 22.60 22.20 21.90 21.50 21.30 20.70 20.70 
U.S. Hispanics age- 






Table 2.3. Joinpoint Analysis Results; Observed Incidence for Malignant Breast Cancer, PR 2000-2013 
    
      Jointpoint Trend 1 Jointpoint Trend 2 Avg. 
APC 
  Age Category  Cases  Years APC Years APC 2009-
2013 
Age at Diagnostic All ages 
  Under 40 years 1,252 2000-2013 3.2^     3.2^ 
  40 to 59 years 8,399 2000-2007 0.01 2007-2013 4.2^ 4.2^ 




  Southeast 1,039  2000-2013 5.9^     5.9^ 
  East 2,101  2000-2013 4.4^     4.4^ 
  North 2,326  2000-2013 3.9^     3.9^ 
  Central 1,764  2000-2013 3.9^     3.9^ 
  Northeast 2,598  2000-2013 2.7^     2.7^ 
  San Juan 2,717  2000-2004 -6.9^ 2004-2013 2.2^ 2.2^ 
  Northwest 1,421  2000-2013 2.4^     2.4^ 
  Southwest 1,581  2000-2013 2.2     2.2 
  NorthMetro 2,916  2000-2013 0.9     0.9 
  West 1,388  2000-2013 0.01     0.01 
  Unknown   377  2000-2013 -11.6^     -11.6^ 
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Age-adjusted incidence and mortality rates for malignant breast cancer in Puerto Rico 
between 2000 and 2013, stratified by histologic type and stage of disease  
Introduction 
Puerto Rico's breast cancer incidence rates are increasing, and mortality rates 
for Puerto Rican (PR) females are higher than those for U.S. females and US Hispanic 
females, warranting analysis of breast cancer rates by other clinical indicators.  
Describing Puerto Rican breast cancer incidence and mortality rates by factors that 
influence prognosis, such as by histologic types, the grade of the tumors, and staging of 
the disease at diagnosis will confirm whether these clinical indicators, typically 
accompanied by a gradient of aggressiveness within breast cancer subtypes, explain 
the high mortality rates in PR females.  Given the aging of the Puerto Rican population, 
it is expected that more advanced stages of the disease will become more prevalent 
among diagnosed breast cancer cases, as other researchers have described for the US 
population (Bush, 1996).   Assessing the magnitude of the problem of diagnoses 
occurring in advanced stages will suggest strategies for improving outcomes, including 
increasing funding allocation for enhancing primary prevention efforts, screening efforts 
in high-risk groups, and improving access to treatment in the initial stages of breast 
cancer. 
Our previous analysis in chapter II of the Puerto Rico Central Cancer Center 
(PRCCC) data demonstrated that the age-adjusted mortality rates were higher among 
PR females than U.S. females overall and U.S. Hispanic females. Additionally, the 




compared to that for U.S. females, has been moving closer to the U.S. level since 2007, 
with breast cancer mortality rising through 2013.   
Improvements in the health services access model allowed Puerto Rican females 
to receive earlier breast cancer screening, earlier diagnostic testing, and access to 
treatment, which might account for the simultaneous increase in incidence since 2006 
and the flattening of the breast cancer mortality curve after 2011.  However, given the 
lower incidence and mortality rates among the USA Hispanic population compared to 
other ethnic groups (Power, 2018), research is needed to explain possible explanations 
for the higher mortality in Puerto Rican women.  
 To our knowledge, no recent study has described trends in the distribution of 
histologic types and tumor grade of breast cancer in Puerto Rico.  Such data would help 
local administrators evaluate governmental and medical providers’ efforts to ensure 
responsible allocation of resources better, reduce the incidence and mortality, and 
improve women's health outcomes with breast cancer in Puerto Rico. The objective of 
this paper is to evaluate trends of breast cancer incidence and mortality rates between 
2000 and 2013 by stage of the disease at diagnosis, histology tumor type, and tumor 
grades to develop a better understanding as to how to improve prevention strategies 






PRCCC provided a file with 29,750 records of breast cancer cases for the period 
between 2000 and 2013. The data file included basic demographic information and the 
following variables: Year of Diagnosis, Primary Site, Vital Status, Tumor Grade, 
Histological Tumor Type, and Stage of Disease at Diagnosis. A total of 9,522 cases did 
not meet the selection criteria below for a final study population of 20,228 malignant 
breast cancer females.   
The following groups were excluded: 
● 260 males 
● 5,783 breast cancer cases with more than 1 primary site to limit breast cancer 
selection only and breast cancer as the primary malignancy.  
● One case living outside of Puerto Rico.  
● 25 cases with unknown age at diagnosis.   
● 38 SEER breast cancer cases were excluded given Hodgkin and Non-Hodgkin 
Lymphomas of All Sites not related to breast cancer diagnostics based on the 
SEER breast cancer criteria for histologic codes: 9590, 9596-9663, 9673-9679, 
9687-9698, 9716-9719, 9725-9726, 9735, 9737-9738.   
https://staging.seer.cancer.gov/eod_public/schema/1.1/lymphoma/ 
● 3,405 in situ cases  
● One case with a tumor morphology in a Borderline status.  
New breast cancer cases by clinical categories were calculated based on female 




State Planning Board (Junta de Planificación de Puerto Rico, 2015).  Finally, age-
adjusted rates were calculated using the U.S. 2000 Census female population estimates 
by age group as the standard population to control the aging population.     Age-
adjusted incidence rates for PR females from 2000 to 2013 were calculated using the 
U.S. Census 2000 Standard Population (PR Census Profile, 2010).  Cancer incidence 
rates were then analyzed in the Joinpoint Regression Program (National Cancer 
Institute, 2020).  Joinpoint regression allows for breaking the incidence trends into time 
segments to identify years in which there was a statistically significant change in trend 
("joinpoints"). For each time segment, the analysis estimates the annual percentage 
change (APC) in the incidence/mortality during that period and determines whether the 
APC is statistically different from zero (no trend) at an alpha level equal to 0.05. 
Mortality cases were identified using the binary type Vital Status field from the 
Registry data file.  Causes of death related to women’s breast cancer diagnoses were 
determined using the breast cancer ICD-10 codes for each identified death.  Breast 
cancer mortality analysis was restricted to breast cancer-related deaths with breast 
cancer-specific ICD-10 codes identified as the cause of death. 
Results 
Table 3.1 describes the clinical characteristics of the 20,228 breast cancer 
patients identified for this study. Sixty-eight (68%) percent of the tumors were from 
Ductal cell carcinomas, followed by Lobular cell carcinomas (11%).  Thirty-five (35%) of 
the tumors were poorly differentiated (G3), followed by 31% of moderately differentiated 




tumors (G1), and almost thirty percent of the tumors had not determined cell types 
(29%).  
In Puerto Rico, 10,767 cases (53%) were classified with a localized stage at 
diagnosis, and twenty-two percent (22%) were classified with a Regional to lymph node 
stage at diagnosis.  A total of 6,199 cases (30%) reported the upper outer quadrant as 
the tumor site at diagnosis.  Fourteen percent (14.6%) manifest overlapping sites for the 
tumor at diagnosis.  Thirty-two (32%) percent of the cases presented Breast (Not 
Specified) sites. Out of the total of 20,228 breast cancer patients, 5,764 cases were 
dead at the time of identification by the Registry, and 3,472 (17%) died from a breast 
cancer-related cause.   
Overall Breast Cancer Incidence Rates in PR 
As shown in chapter II, the adjusted malignant breast cancer incidence rate in 
Puerto Rico increased from 63.04 in 2000 to 81.03 cases per 100,000 person-years in 
2013, an annual percent change of 2.1 per year. Incidence rates started to increase in 
2006 and rose through 2013 with a statistically significant annual percent change close 
to 4% (APC=3.63; (p-value <0.00016) (Figure 3.1).   
Breast Cancer Incidence by Histologic Type 
The most prevalent reported histology among the Puerto Rico breast cancer 
cases for the period was infiltrating ductal cell carcinoma (Table 3.1).  Ductal cell-
specific incidence rates slightly increased between the years 2000 to 2009.  A non-
significant annual percent change of close to 1% per year (APC=1.2%; (p-value of 
0.07). The incidence rate was 44.7 in 2000 to 47.96 cases per 100,000 females in the 




sharp increase between the 2009 to 2013 period with a statistically significant increase 
of 7% annually (APC=6.7; p-value of 0.0151). The rate increased from 48 cases per 
100,000 females in 2009 to 62 cases per 100,000 females in 2013. These patterns are 
illustrated in Figure 3.2 and Table 3.2.   
For the patients with “Lobular and other ductal carcinomas,” the rates showed a 
slight and statistically significant increase of approximately 2% per year (APC=1.87%; 
(p-value of 0.0021) (Figure 3.3). The incidence rate increased from 7.1 new cases per 
100,000 females in 2000 to 8.3 new cases in 2013.  
 Incidence rates for patients with Mucinous histological types carcinomas show a 
small but statistically significant increase close to 3% annually (APC= 3.11%; p-value of 
0.0177) (Figure 3.4).  The incidence rate was 1.40 per 100,000 females in 2000 and 
1.61 per 100,000 females in 2013.   
Incidence rates for breast cancer cases with the Medullary histological type 
carcinomas presented a statistically significant reduction of close to 10% per year 
(APC=9.6%; p-value of 0.0005) (Figure 3.5). The rates rose from 1.19 per 100,000 
females in the year 2000 to 0.34 per 100,000 females in 2013.  
Incidence rates for breast cancer cases with Papillary histological type were 
showed a non-significant annual percent change close to 3% per year (APC=2.71%; p-
value of 0.41) (Figure 3.6).  The rate was 0.47 per 100,000 females for the year 2000 
and 0.47 in 2013.   
Breast cancer cases with rare histological types presented a small but not 
statistically significant increase in the incidence rates with an annual percent change 




in the year 2000 was 0.89 per 100,000 females in the year 2000 and 0.84 per 100,000 
females in the year 2013.  
Breast cancer cases with “Other” histological types presented a slight, non-
statistically significant decrease in the incidence from 2000 to 2013, APC=0.08%; p-
value of 0.94 (Figure 3.8).  The rate in the year 2000 was 7.28 per 100,000 females in 
the year 2000 and 7.37 per 100,000 females in the year 2013.  
Breast Cancer Incidence by Tumor Grade  
 
Breast cancer incidence rates for patients with “Well-differentiated” tumor grades 
presented a statistically significant increase during the study period with an annual 
percent change of 5% per year, APC= 4.78; p-value of 0.00002 (Figure 3.9 and Table 
3.2).  The incidence was 5.74 per 100,000 for 2000 and 9.44 per 100,000 females in 
2013.  
Incidence rates for cases with the “Moderately differentiated” types were stable 
between 2000 and 2009.  The annual percent chance for the first part of the period was 
close to 0% (APC=0.24; p-value of .77).  The incidence rate for the year 2000 was 
22.56 per 100,000 and 23.97 per 100,000 females for the year 2013.  However, in 2010, 
there was a statistically significant increase that continued through 2013. An annual 
percent change of 7% (APC=7.31%; p-value of 0.0176) (Figure 3.10).  The incidence 
rate for the year 2010 was 22.89 per 100,000 and 30.11 per 100,000 females for the 
year 2013.   
Breast cancer incidence rates for patients with “Poorly differentiated” tumor 
grades presented a statistically significant increase with an annual percent change 




incidence rate of 15.12 per 100,000 females in the year 2000 per 100,000 and 20.23 
per 100,000 in 2013.    
Incidence rates for cases with undifferentiated cell types presented a non-
significant decrease during the years 2000 to 2013 with a negative annual percent 
change close to 3% APC=-3.06%; p-value of 0.2 (Figure 3.12).  An incidence rate of 
1.05 per 100,000 for the year 2000 and a rate of 0.028 per 100,000 females for 2013.   
Cases with undetermined grade presented a “U” shape curve for the incidence 
trend.  A non-statistically significant decrease was first observed from 18.57 per 
100,000 in the year 2000 and 13.30 per 100,000 in 2002 (APC= -17.02; p-value of 
0.1929).  Then, a stable segment trend was observed from 2002 to 2011.  
Subsequently, the trend showed a non-significant increase in incidence from 11.92 per 
100,000 and 21.08 per 100,000 from 2011 to 2013.  The annual percent change 
observed was 28.97%, with a p-value of 0.0625 (Figure 3.13).  
Breast Cancer Incidence by Stage 
Breast cancer incidence rates for patients with Localized State at Diagnosis 
presented a statistically significant increase between 2000 and 2014.  The annual percent 
change was close to 3% per year (APC= 2.97%; p-value of 0.00008) (Figure 3.14 and 
Table 3.2).  The observed incidence rate for the year 2000 was 29.70 per 100,000 females 
and 41.42 per 100,000 for the year 2013.    
The observed breast cancer incidence rates for patients with the “Regional to 
Direct extension” stage showed a statistically significant increase from 2000 to 2009, with 
an annual percent change close to 9 percent per year (APC=9.42; p-value of .0012), 




and 4.93 per 100,000 females in the year 2008.  In contrast, starting in 2009, there was 
a statistically significant decrease that lasted until 2013.  The negative annual percent 
change was close to 24% (APC=-23.93%; p-value of 0.0041).  An observed incidence 
rate of 5.29 per 100,000 was observed in 2009 and 1.94 per 100,000 in 2013. 
Incidence rates for breast cancer patients with the “Regional to Lymph node” stage 
were stable between 2000 and 2009.  The annual percent change during this period was 
close to cero APC=-0.43%; p-value of 0.60.  An incidence rate of 13.50 per 100,000 
females was observed for the year 2000 and a rate of 11.5 per 100,000 females for the 
year 2013.  However, in 2010, there was a statistically significant increase with an annual 
percent change close to 10% per year (APC=10.25%; p-value of 0.0032) (Figure 3.16). 
The observed rate for 2010 was 15.32 per 100,000 and 19.71 per 100,000 for the year 
2013.   
The observed breast cancer incidence rates for patients with “DE and lymph node” 
stages also showed a statistically significant increase from 2000 to 2008, starting with an 
incidence rate of 1.71 per 100,000 and 1.94 per 100,000, respectively. The annual 
percent change observed was 7.53%, with a p-value of 0.0243. In contrast, there was a 
statistically significant decrease starting in 2008. The annual percent change was 13.37% 
with a p-value of 0.0012 (Figure 3.17).   
Breast cancer incidence rates for patients with “Distant Stage” reflected a non-
statistically significant increase for the 2000 to 2013 period. The annual percent change 
in the period was close to 2% (APC=1.55%; p-value of 0.0738) Figure 3.18.  The 
incidence rate observed for the year 2000 was 2.61 per 100,000 in 2000 and 4.40 per 




Cases with an unknown stage at diagnosis presented a “U” shaped curve for the 
incidence trend.  A statistically significant decrease was observed from the year 2000 to 
the year 2002. The negative annual percent change is close 40% (APC= -40.43%; p-
value of 0.03). A rate of 12.92 per 100,000 females was observed for 2000 and a rate of 
4.18 per 100,000 in 2002. Subsequently, a stable segment from 2003 to 2011 was 
observed (APC=0.97%; p-value of 0.7113).  A rate of 4.53 per 100,000 females for the 
2003 year and a rate of 4.19 per 100,000 females during 2010.   From 2011 to 2013, 
though, the incidence rates showed a non-significant increase from 4.03 per 100,000 to 
10.92 per 100,000, respectively. The annual percent change observed was close to 
50% per year (APC=49.19%; p-value of 0.06), Figure 3.19. 
Overall Mortality Rates for Breast Cancer 
Out of a total of 20,228 breast cancer patients, 5,764 cases (28.5%) were dead 
at the time of identification by the registry, and 3,472 (17%) died from a breast cancer-
related cause.  The age-adjusted malignant breast cancer mortality rate in Puerto Rico 
increased from 3.6 deaths per 100,000 females in 2000 to 24.8 deaths per 100,000 
females in 2014.    After 2007, mortality rates increased with an annual percent change 
of 2% (p-value = 0.2), reaching a rate in 2014 of 25 per 100,000 females.   The Puerto 
Rican age-adjusted mortality was higher than the USA age-adjusted mortality and the 
USA Hispanics' age-mortality rates (Figure 3.20).  The age-adjusted mortality rates for 
Puerto Rico decreased from 26.85 deaths per 100,000 females in 2012 to 24.7 deaths 




Mortality Rates by Histologic Type 
Out of 3,274 reported breast cancer deaths, 2,346 deaths (68%) were 
attributable to infiltrating duct cell carcinomas. Notably, this was the only histologic type 
showing a significant increase compared to the other types during the study period 
(Figure 3.21).  Six hundred and forty-three (643) deaths from lobular and other types of 
ductal carcinomas represented 11% of the deaths for that period.  Rare subtypes of 
histological types accounted for 3% of the deaths, while mucinous adenocarcinomas 
and medullary carcinomas each represented 1% of the breast cancer deaths on the 
Island (Table 3.1).   
The mortality rates for Infiltrating ductal cell carcinomas increased from 0.42 
deaths per 100,000 females in 2000 to 10.1 deaths per 100,000 in 2014.  Lobular cell 
carcinomas' mortality rate increased from 0.11 deaths per 100,000 females in 2000 to 
1.17 deaths per 100,000 in 2014. The mortality rate for Mucinous adenocarcinomas, 
Medullary carcinomas, and Papillary carcinomas remained stable throughout the study 
period.  For Mucinous adenocarcinomas, the rates increased from 0 in 2000 to 0.15 
deaths per 100,000 females in 2014. The mortality rate for Medullary carcinomas 
increased from 0 in the year 2000 to 0.15 deaths per 100,000 females in 2014 and for 
papillary carcinomas from 0.6 to 0 in 2014. The other subtypes category decreased 
from 1.55 deaths per 100,000 to 0. 
Breast Cancer Mortality by Grade 
 
Out of 3,472 breast cancer-related deaths, 1,210 (34.9%) were attributable to 
“poorly differentiated” (Grade 3 tumors).  A total of 1,070 (30.8%) deaths were 




(1.8%) were attributable to undifferentiated tumors (Grade 4).  For 1,013 deaths (29%), 
the grade was not determined for the tumors' cell types (Table 3.1).   The trend in the 
mortality rates for poorly differentiated (Grade 3) increased more for the period followed 
by moderately differentiated (Grade 2) tumors, which also increased consistently during 
the study period (Figure 3.22). 
Mortality Rates by Stage 
 
Out of 3,472 breast cancer-related deaths, 1,564 (45%) deaths were identified 
with a localized stage.  A total of 794 (23.9%) were identified at a regional stage, and 
562 deaths (16.2%) were diagnosed at a distant stage. There was also a total of 552 
deaths (15.9%) that were either unstaged, unspecified or with an unknown stage at 
diagnosis (Table 3.1).    
The percent distribution of deaths by stage of the disease at diagnosis and year 
is summarized in Table 3.3.  Summarized age-adjusted mortality rates trends by stage 
and stage were graphically summarized in Figure 3.23.  For breast cancer cases with a 
regional stage at diagnosis showed the highest mortality in the study period.  A sharp 
increase was observed in the adjusted death rates starting with 0.15 per 100,000 
females in the 2000 year to 6.78 deaths per 100,000 females in 2014.  The age-
adjusted death rates for patients with a localized stage at diagnosis increased from 0.1 
deaths per 100,000 females to 3.24 deaths per 100,000 in 2014. 
The third highest mortality trend line was for patients with distant metastasis 
increasing from a rate of 0.28 in 2000 to 1.73 in 2014. Finally, those patients with an 
unknown stage at the time of diagnosis showed a slight reduction in the study period 




Like all ecological analyses of population-level data, this study is subject to 
several limitations. First, given the ecological nature of the investigation, no conclusions 
can be made regarding potential causal factors behind the observed trends Selection 
bias, common to cancer registry-related studies, might have occurred if local health 
providers reported incomplete case ascertainment and/or not all cases to the Cancer 
Registry.   The mortality information for cases identified by the registry was less 
documented in the early years of the study period, which correlates to the first years of 
the registry's re-implementation. 
To our knowledge, no recent publication has described trends in the distribution 
of breast cancer cases by histologic types, tumor grade, and stage of the disease in 
Puerto Rico.  It concerns that female breast cancer in PR shows a statistically 
significant increase in Type III histological types (Infiltrating ductal and lobular 
carcinomas). This finding correlates with a similar increase in more aggressive tumor 
types, Grade 2 (Moderately differentiated) and Grade 3 (Poorly differentiated), and may 
underlie the observed increases in mortality. 
The increase in localized tumors likely reflects the success of screening efforts in earlier 
identification of the disease. More research is needed to understand better the reasons 
for the observed increases in mortality associated with Type III and Grade 2 cancers. 
More research is also necessary to understand the reasons for the rise in cases and 
mortality in the Regional to Lymph Nodes stage in the most recent period (2009 - 2013). 
Discussion 
The objective of this paper was to evaluate trends of incidence and mortality 




type, and tumor grades to provide a better understanding as to how to improve 
prevention strategies aimed at reducing new cases and deaths in PR females for breast 
cancer. To our knowledge, no recent publication has described trends in the distribution 
of breast cancer cases by histologic types, tumor grade, and stage of the disease in 
Puerto Rico.   The data presented here provide vital information for public health 
stakeholders to better understand breast cancer cases' clinical profile and improve 
resource allocation to reduce the incidence and mortality of women with breast cancer 
in Puerto Rico.  A total of 20,228 malignant breast cancer cases in Puerto Rico were 
analyzed for the 2000 to 2014 period.  Regarding incidence, the analysis showed a 
sharp and significant increase in the incidence of infiltrating ductal cell carcinomas. The 
use of newer and more sophisticated diagnostic modalities among pathologists might 
have resulted in a more straightforward and more precise identification of histological 
types.  With the new resources made available through the Health Reform and the 
Medicare Advantage programs, more cases may also have been referred for 
pathological evaluation. Incorporating more resources from the University of Puerto 
Rico, now administering the Registry, might have improved these clinical details.  
However, the possibility that environmental exposures may account for the observed 
increases cannot be discarded. Statistically significant increases were documented for 
lobular and Mucinous cell carcinomas for the study period.  In contracts, Medullary 
carcinomas showed a statistically significant reduction in rates for the study period.  
Papillary carcinomas showed a statistically insignificant increase for the period, and 




Similar to infiltrating ductal cell carcinomas, new cases with moderately 
differentiated tumors were stable from 2000 to 2009, but a sharp and statistically 
significant increase was observed from 2009 to 2014.  Similar to infiltrating ductal 
carcinomas, this observed increase may be attributable to the use of newer and more 
sophisticated diagnostic modalities among pathologists, further resources from the 
Health Reform and the Medicare Advantage programs leading to more referrals for 
pathological evaluation, the improved abstraction of clinical details from the medical 
record, or to as yet unknown environmental factors. Malignant breast cases with well-
differentiated and poorly differentiated tumors increased steadily for the whole period.  
The incidence of breast cancer with undifferentiated type tumors decreased for the 
study period. 
Regarding the disease stage and similar to infiltrating ductal cell carcinomas, 
cases with a Regional to lymph node stage were stable from the year 2000 to 2009, 
with a sharp and statistically significant increase from 2009 to 2014.  Localized tumors 
like tumors with well and poorly differentiated grades showed a constant rise in 
incidence rates for the whole period. Given the increase in incidence and mortality rates 
on poorly differentiated tumors (Grade 3) more attention needs to be allocated to 
patients in early stages with more aggressive tumors to receive targeted chemotherapy, 
to help destroy any cancer cells that may have spread as a result of the cancer being 
faster growing (Breast Cancer Now Org, 2020).  
More aggressive tumors and tumors with a regional to lymph nodes stage 
increased after 2009, which is correlated with the increase in combined estrogen and 




documented since 2002 to increase breast cancer risk (Lee and colleagues, 2003).  
However, this correlation has not been investigated in Puerto Rican women. 
This study had two main limitations.  First, the lack of information on the patient’s 
type of health insurance in the registry data limited our ability to assess the role of 
insurance access.  Second, mortality information for cases identified by the registry in 
the early years of the study period was limited, which correlates to the first years of the 
registry's re-implementation.  Incomplete case ascertainment information is also 
possible if health providers did not report all Cancer Registry cases, a common potential 
bias in cancer registry-related studies. 
In this chapter, age-adjusted incidence and mortality rates trends were described 
by histologic types, the grade of the tumor, and stage of the disease at diagnosis in 
Puerto Rico for the 2000 to 2013 period; To our knowledge, no recent publication has 
described trends in the distribution of new breast cancer cases and mortality by 
histologic types, tumor grade and stage of the disease in Puerto Rico.  It is concerning 
that women with breast cancer in PR show a statistically significant increase in Type III 
histological types (Infiltrating ductal and lobular carcinomas). This finding correlates with 
a similar increase in more aggressive tumor types, Grade 2 (Moderately differentiated) 
and Grade 3 (Poorly differentiated), and may underlie the observed increases in 
mortality.  The observed rise in cases with localized tumors likely reflects the success of 
screening efforts in earlier identification of the disease.  Notwithstanding, more research 
is needed to understand better reasons for the increase in mortality associated with 
Type III and Grade 2 cancers and to understand reasons for the rise in cases and 




2013).  We suggest that this reporting method will become a standard and become an 
integrated and systematic section in the reporting for future cancer publications in 
Puerto Rico.  However, limited information on deaths from 2000-2005 may have biased 
the trend analysis in this early period.   
The next chapter will provide an applied example of the experience of medical 
and prescription utilization of a Medicare breast cancer population in Puerto Rico. Care 
coordination and significant funding were allocated to this segment of the population, 




Table 3.1 Puerto Rico Malignant Breast Cancer Cases Characteristics; 2000 to 2013 
   Malignant    In-Situ 
Histology Cases % Deaths % 
 
Cases % 
Ductal Carcinoma 14,728 72.8% 2,346 68% 
 
1,588 47.0% 
Lobular and Other Ductal CA 2,637 13.0% 365 11% 
 
1,002 29.7% 
Mucinous Adenocarcinoma 558 2.8% 40 1% 
 
2 0.1% 
Medullary Carcinoma 187 0.9% 19 1% 
 
- 0.0% 
Papillary Carcinoma 119 0.6% 5 0% 
 
23 0.7% 
Rare Subtypes 268 1.3% 87 3% 
 
356 10.5% 
Others 1,731 8.6% 610 18% 
 
405 12.0% 
Total 20,228 100.0% 3,472 100% 
 
3,376 100.0% 
Tumor Grade Cases % Deaths % 
 
Cases % 
Well diferrentiated (G1) 2,247 11.1 117 3.4% 
 
546 16.2% 
Moderately diferrentiated (G2) 7,612 37.6 1,070 30.8% 
 
964 28.6% 
Poorly differentiated (G3) 5,671 28.0 1,210 34.9% 
 
481 14.2% 
Undifferentiated (G4) 289 1.4 62 1.8% 
 
237 7.0% 
Cell type not determined 4,409 21.8 1,013 29.2% 
 
1,148 34.0% 
Total 20,228 100.0 3,472 100.0% 
 
3,376 100.0% 
Stage at Diagnosis Cases % Deaths % 
   
Localized 10,767 53.2 794 22.9% 
   
Regional by direct extension 966 4.8 257 7.4% 
   
Regional to lymph nodes 4,422 21.9 912 26.3% 
   
Regional (direct extension and lymph 
nodes) 
1,225 6.1 387 11.1% 
   
Regional, NOS 20 0.1 8 0.2% 
   
Distant metastasis or systemic 
disease (leukemia, multiple myeloma) 
1,061 5.3 562 16.2% 
   
Unstaged, Unknown,Unspecified 1,767 8.7 552 15.9% 
   
Total 20,228 100.0 3,472 100.0% 
   
Site Cases % Deaths % 
 
Cases % 
Nipple 230 1.1% 36 1.0% 
 
30 0.9% 
Central Portion of the Breast 740 3.7% 108 3.1% 
 
172 5.1% 
Upper inner quadrant 1,563 7.7% 176 5.1% 
 
211 6.3% 
Lower inner quadrant 876 4.3% 121 3.5% 
 
151 4.5% 
Upper outer quadrant 6,199 30.6% 899 25.9% 
 
1,012 30.0% 
Lower outer quadrant 1,091 5.4% 145 4.2% 
 
156 4.6% 
Axillary tail 154 0.8% 33 1.0% 
 
9 0.3% 
Overlapping 2,945 14.6% 381 11.0% 
 
460 13.6% 
Breast, NOS 6,430 31.8% 1,573 45.3% 
 
1,175 34.8% 
Total 20,228 100.0% 3,472 100.0% 
 
3,376 100.0% 
Vital Status Cases % 
     
Dead 5,764 28.5 
     
Alive 14,464 71.5 
     
Breat Cancer related Death Cases % 
     
Yes 3,472 17.2 





Table 3.2 Joinpoint Analysis Results; Observed Incidence for Malignant Breast Cancer, PR 2000-2013 
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Table 3.3 Percent Distribution of Breast Cancer-related Deaths by Year and Stage at Diagnosis 
Stage 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 
Localized 5 9 21 20 20 22 23 26 25 25 22 27 21 23 26 
Regional by Direct 
Extension (DE) 
0 4 6 5 6 7 8 7 7 7 10 7 10 8 7 
Regional to Lymph 
Nodes 
5 20 19 31 23 23 35 23 24 25 26 27 25 30 31 
Regional (DE and 
Lymph nodes) 
2 5 12 8 7 9 8 13 11 11 15 14 13 10 15 
Regional NOS 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 
Distant 14 20 15 13 24 17 15 15 14 18 13 16 17 19 14 
Unknown 74 41 25 23 20 20 11 16 19 14 13 9 13 9 7 
Total 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 
 



























































































































2007-2013 APC = 3.63^
^ The Anual Percent Change (APC) is significantly different from zero at alpha level = 0.05










































































































2009-2013 APC = 6.37^
^ The Anual Percent Change (APC) is significantly different from zero at alpha level = 0.05
Final Selected Model: 1 Joinpoint.
Figure 3.21 Malignant Breast Cancer Age-Adj Incidence Rates for PR 2000-2013 














































































































^ The Anual Percent Change (APC) is significantly different from zero at alpha level = 0.05
Final Selected Model: 0 Joinpoints.








































































































^ The Anual Percent Change (APC) is significantly different from zero at alpha level = 0.05
Final Selected Model: 0 Joinpoints.























































Figure 3.25 Malignant Breast Cancer Age-Adj Rates with Medullary Carcinoma 










































































































^ The Anual Percent Change (APC) is significantly different from zero at alpha level = 0.05









































































































^ The Anual Percent Change (APC) is significantly different from zero at alpha level = 0.05



































































































































^ The Anual Percent Change (APC) is significantly different from zero at alpha level = 0.05









































































































^ The Anual Percent Change (APC) is significantly different from zero at alpha level = 0.05
Final Selected Model: 0 Joinpoints.
Figure 3.27 Malignant Breast Cancer Age-Adj Rates with Rares Subtypes 





















































































































^ The Anual Percent Change (APC) is significantly different from zero at alpha level = 0.05






































































































2009-2013 APC = 7.53^
^ The Anual Percent Change (APC) is significantly different from zero at alpha level = 0.05
Final Selected Model: 1 Joinpoint.

















































Figure 3.32 Malignant Breast Cancer Age-Adj Rates for Undifferentiated 
Figure 3.31 Malignant Breast Cancer Age-Adj Rates for Poorly differentiated 
15 15
18 18































































































^ The Anual Percent Change (APC) is significantly different from zero at alpha level = 0.05











































































































^ The Anual Percent Change (APC) is significantly different from zero at alpha level = 0.05




Figure 3.33 Malignant Breast Cancer Age-Adj Rates for Localized Disease Stage 





































































































2002-2011 APC = 0.37
2011-2013 APC = 30.14
^ The Anual Percent Change (APC) is significantly different from zero at alpha level = 0.05






































































































^ The Anual Percent Change (APC) is significantly different from zero at alpha level = 0.05





Figure 3.36 Malignant Breast Cancer Age-Adj Rates with Regional by Direct Extension Stage 









































































































2009-2013 APC = -23.93^
^ The Anual Percent Change (APC) is significantly different from zero at alpha level = 0.05








































































































2008-2013 APC = -13.37^
^ The Anual Percent Change (APC) is significantly different from zero at alpha level = 0.05










Figure 3.37 Malignant Breast Cancer Age-Adj Rates with Regional to lymph node Staging 





































































































2009-2013 APC = 10.25^
^ The Anual Percent Change (APC) is significantly different from zero at alpha level = 0.05












































































































^ The Anual Percent Change (APC) is significantly different from zero at alpha level = 0.05
























































































































2002-2011 APC = 0.97
2011-2013 APC = 4029
^ The Anual Percent Change (APC) is significantly different from zero at alpha level = 0.05































































Figure 3.40 Breast Cancer Mortality Rates for PR and USA 
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A ten-year population treatment profile of breast cancer cases in a Medicare Advantage 
Independent Practice Association in Puerto Rico 
 
Introduction 
Access to health services in Puerto Rico for the medically indigent population 
changed when the government established a Health Reform initiative in 1994. This 
initiative gave health insurance companies an essential role in administering health 
service provision to the medically indigent population.  The Health Reform initiative in 
the Island was implemented by stages starting in 1994 and concluding in 2000. 
Similarly, in 2006, Puerto Rican (PR) Medicare beneficiaries were now able to enroll in 
a Medicare Advantage (MA) plan, a type of Medicare health plan (Part C) offered by a 
private health insurance company that contracts with Medicare to provide Part A, Part 
B, and Part D benefits.  Given the minimal to no co-payments and enhanced benefits in 
these MA plans, their popularity saw an MA penetration of almost 80% among the 
eligible Medicare beneficiary population. (Keyser, 2014). 
The new Medicare Advantage companies were now locally administering the 
coordination of screening services and supporting primary care health providers with 
coordination of care, including cancer screening and cancer treatment modalities for 
many Medicare patients, who had lacked many of these opportunities before introducing 
these MA plans.   In 2012, a total of 483,978 persons, 75% of the Medicare-eligible 
population, were enrolled in a MA plan in Puerto Rico (Keyser, 2014).  The 
implementation of the Medicare Advantage program in Puerto Rico resulted in more 




services and treatment options.  As shown in paper one, breast cancer data analysis 
shows that the age-adjusted incidence increased in the island, starting in 2006, the year 
the Program began. 
Castellana’s Physician Services is an Independent Practice Association (IPA) 
with approximately 400 primary health care providers serving about 30,000 female 
patients over the age of 65.  This number represents 11% of the Medicare Advantage 
female population of Puerto Rico.  The IPA Castellana exclusively managed Medicare-
eligible members in four Geographical Regions on the north and east side of the Island.  
Thus, findings in this population likely represent the best standard of care in Puerto Rico 
for the elderly population.  Castellana is exclusively contracted with one MA plan called 
MMM. MMM was the first MA plan to achieve the Centers for Medicare and Medicaid 
Services (CMS) five-star rating and continues to hold the highest-rated star ranking 
among all plans on the Island (MMM website, 2020).  
This study aims to analyze the distribution of breast cancer cases seen within the 
Castellana system by year and the related pharmaceutical and medical services 
utilization during the study period.  No study has described, to our knowledge, the 
pharmaceutical and medical treatment modalities provided to breast cancer patients 
since the implementation of the Medicare Advance program on the Island.  Analyzing 
these patterns will help evaluate the extent of breast cancer treatment guidelines and 






To describe this breast cancer population, a claims analysis was conducted 
using linked de-identified patient’s files with pharmacy and medical claims information 
for the period of April 1, 2007, to Oct 20, 2016, paid as of Oct 21, 2016. Files were 
provided after receiving approval from the Castellana administration and the MMM 
health plan compliance officer.  Data analyses were conducted using the SAS version 
9.4, and Epi-Info version 7.2.2.6, the Center for Diseases Control (CDC) Epidemiologic 
Software System. 
To identify breast cancer patients, three steps requiring data linkage were 
needed:  First, we identified all patients in the medical claims database with a breast 
cancer diagnosis.  Only medical claims with breast cancer codes based on the WHO 
International Categorization of Diseases (ICD-9) codes within any of the first four 
diagnostics field positions in the claim (Table 4.1) were included. This inclusion criterion 
was applied to the 2,538,701 lines of medical claims. Laboratory and radiological claims 
were not considered because such claims could be the result of a screening effort. 
However, as not all breast cancer patients might have a medical claim with breast 
cancer ICD-9 codes, a second step was then undertaken to ensure that a better 
identification of breast cancer patients occurred. Using the pharmacy claims files, 
Patients were selected if using antineoplastic drugs indicated for breast cancer by the 
Federal Drug Administration.  Identified cases were merged with the first group, and 
duplicate patients were deleted.  A third step was done to obtain all their pharmacy 
drug-related utilization for the study period with all breast cancer patients identified.  We 
filtered a total of 1,159,253 lines of pharmacy utilization claims files to locate only those 




done to gather all pharmacy utilization from the pharmacy claims dataset.  Finally, all 
their medical claims utilization files were built to study the treatment profiles.  
Data Management  
Merged dataset sets were analyzed using the CDC Epi-Info and SAS statistical 
software.  Descriptive statistics were generated for the study population.  For the 
geographical plotting analysis, the latitude and longitude coordinates for each 
municipality were used to plot each case residing in a given municipality using the EPI-
Info maps software module.  
Results 
A total of 5,112 unique female breast cancer patients were identified from the 
medical claims file.   Eighty-five (85) cases out of these 5,112 claims were not identified 
in the demographic file.  As a result, 5,027 cases had both medical claims and 
demographic related information. However, to maximize the provided information, 5,112 
represented the analytical sample.   We evaluated the percentage of patients who 
remained continuously active in the Health plan during the study period receiving 
services by the Health plan and were under the clinical guidance of a Primary Care 
Physician (PCP) in the Castellana Group.   A total of 1,009 (20.5%) cases were active in 
the IPA since April 2004. By June 1, 2016, 2,902 (57%) of the breast cancer patients 
were still active and receiving services coordinated by the IPA's primary care physicians 
(Figure 4.1). To be non-active, a member (patient) might have decided to change to a 
different PCP, not under the Castellana Group, or the patient may have died.    
Of the 5,027 Castellana’s breast cancer cases, 85% were over 65 years of age 




the cases was 73 years, the minimum reported age was 35, and the maximum was 106 
years of age. 
The identified patients' geographical residence was clustered; cases were 
concentrated from the middle to the east part of the Island, where the Castellana’s 
provider network renders services (Table 4.2 and Figure 4.1).  This is consistent with 
the allocation of the geographical locations of the Castella Primary Care Physicians’ 
offices. Figure 4.2 provides the distribution of cases over time, stratified by location. Of 
the cases, 64% were also State-funded, or as called by the Government, were 
“Platinos”, which signifies that they were under the 200%-poverty federal income level.  
During the study period, close to 30% of the breast cancer patients received at least 
one breast cancer specialty drug, derived from the pharmacy claims files, to treat their 
condition (Table 4.2).  
Prescription Utilization Summary among Breast Cancer Patients 
A total of 880,884 prescriptions were identified and paid out of the pharmacy 
claims file from the 5,112 breast cancer patients.  The number of medications (any 
prescription) per case increased from 2.7 prescriptions per case in January 2008 to 3.5 
prescriptions per case in October 2016 (Figure 4.3), 
The Hormonal and Related Agents (HRA) Drug Category, 13,215 breast cancer 
Specialty Drugs prescriptions, were identified as dispensed in pharmacies across the 
Island from the largest categorical group.   Of these, 98% were administered orally, and 
13,033 (98.62%) were within the Antineoplastic - HRA drug classification category 
(Table 4.3). The Identified used drugs and drug categories within this study population 




Inhibitors accounted for 73.7% of the total prescriptions for the study period followed by 
antiestrogens with 24.9 of the prescriptions (Table 4.5).  The use of Aromatase 
Inhibitors increased from 60% in the year 2008 to 74% in 2016. 
In contrast, the use of Antiestrogen decreased from 40% in the year 2006 to 14% 
in the year 2018. (Figure 4.4). To further analyze the use of Aromatase Inhibitors versus 
the use of Antiestrogens, the prescriptions per breast case were analyzed.  The number 
of prescriptions for Aromatase Inhibitors per breast cancer case significantly increased 
from .10 prescriptions per case in 2008 to almost one prescription per case (.77) in 
2016.   The number of prescriptions per case for Antiestrogens remains stable during 
the period with .06 prescriptions for the year 2008 compared to .11 prescriptions per 
case in 2016 (Figure 4.7). 
To evaluate the Breast Cancer patient's drug utilization by intravenous 
administration, all injectables were identified from the Medical Utilization Datafile.  A 
total of 1,884,744 claims from injectables services were identified from the breast 
cancer case medical data file with a median of 3.8 injectable services per case in 2010, 
increasing to a median of six injectable services per breast cancer case in June 2016 
(Figure 4.6).   
Specifically, for breast cancer related injectable drugs, a total of 231,660 claims 
(3%) were identified from the breast cancer specialty drugs list (Table 4.6).  Most of the 
claims (78%) indicate that breast cancer cases undergoing specialty drug treatment 
were treated at the medical provider doctor’s office (oncologists). Paclitaxel is the most 




Medical Service Categories 
Out of the 2,538,701 service claims, a total of 188,227 were identified with a 
breast cancer code as the principal diagnosis in the service claim.    Services increased 
consistently across the study period and were coded to service categories based on the 
American Medical Association’s Coding Standard.  The number of services per case 
increased across the study period from 64.8 services per case per year in 2007 to 110.5 
services per case per the year in 2015 (Table 4.7).  
The main categories of services rendered for the Breast Cancer patients were 
Office/other outpatient services (16%), Injectable drugs (13%), Radiation and Oncology 
(12%), and Chemotherapy (10%).  Those services were mainly rendered in the office 
setting (56%), in Independent Laboratories (22%), and the On Campus-Outpatient 
Hospital setting 15%. (Table 4.8 & 4.10).  For breast cancer as a primary diagnosis, all 
services categories increased except for the service category of Radiation Oncology, 
which presented a major drop in 2013 (Table 4.9 & 4.11).   
Surgical Procedures 
A total of 985 out of 5,112 breast cancer patients had mastectomy procedures 
during the studio period.  This accounts for 20% of the population (Figure 4.8).  The 
procedure (19301) of “Mastectomy, partial” (e.g., lumpectomy, tylectomy, 
quadrantectomy, segmentectomy) increased from 39.5% of cases in 2007 to 57.28% in 
2016.  In contrast, the procedure (19302) “Mastectomy, partial with axillary 
lymphadenectomy” (e.g., lumpectomy, tylectomy, quadrantectomy, segmentectomy); 






 This study's objective was to describe the demographic characteristics of a 
Medicare Advantage breast cancer population in Puerto Rico and analyze the utilization 
of pharmaceutical and medical services for breast cancer treatment during the study 
period.   An analysis of the trends and types of treatment using claims paid data from a 
private health plan will help evaluate if there was more and better adoption of treatment 
guidelines during this period, identifying areas of opportunity for improvement.    
The analysis demonstrated an increase in the utilization of services in pharmacy 
claims and medical service claims.  By the end of the study period, more patient services 
were available to the breast cancer population of the Medicare Independent Practice 
Association (IPA) of Primary Care Physicians. Prescriptions per case and injectables per 
case both increased.  The percent receiving aromatase inhibitors also increased during 
the study period.  In contrast, the use of antiestrogens decreased.  A lack of estrogen 
receptor and progesterone receptor testing may be one of the reasons for this decrease.  
Our prior study of the Puerto Rico Central Cancer Registry identified the registry's lack of 
information on receptor data. These facts raise the question of whether providers are not 
ordering these tests or whether the health plan is not approving them, given the lack of 
evidence for the corresponding therapy. This question requires further research. 
Among the medical utilization services, we observed increases in the medical 
provider office setting category. Primary care physicians and oncologists evaluated more 
breast cancer cases, and care and coordination of services were increased by the IPA 
and the health insurance company during the study period.  The percent of independent 
laboratory utilization also increased during the study period, showing more access to the 




direct effect of more patients visiting the providers at their office instead of using a hospital 
setting for preventive ambulatory services. One of the specific breast cancer treatment 
modalities evaluated in this study was mastectomy utilization among this population.  The 
overall percentages of partial mastectomies increased during the period, suggesting 
better adoption of treatment guidelines in this population (National Comprehensive 
Cancer Network, 2020).   
The main strength of this study was to perform a complementary analysis of 
breast cancer incidence and mortality data evaluating the course of diagnosis and 
treatment using an electronic claims-based dataset.  This method helps to describe the 
time of diagnosis and treatment using billed services and diagnostics codes billed by 
service providers to a private health plan.  The use of health insurance data allows us to 
study prevention screening efforts, diagnosis, surgical procedures, and prescribed drug 
therapies used for treatment during the disease.  It also provides information on the type 
of service providers who participated in the diagnosis and treatment stages.  This 
information is not available in the State Cancer Registries.  Reliable data is derived from 
health plans given that they are subject to audits by multiple federal and local entities of 
their validity to safeguard the fiscal sources of the patients and the government.  Some 
of these entities are:  Center of Medicaid and Medicare, the Department of Health of 
Puerto Rico, “Oficina del Comisionado de Seguros de Puerto Rico,” NCQA certified 
auditors and private auditing companies.  Nonetheless, this data has some limitations 
such as variability due to the multiple coders, possible errors when billing, and lack of 
information on the results of procedures and laboratory services, as the only information 




of data requires programming and coding expertise not necessarily available at the 
Cancer registries, which might be an economic and procedural challenge for small 
Registries to achieve. 
In summary, these data suggest that breast cancer patients' treatment improved 
among Medicare female beneficiaries across the study period, consistent with the findings 
of Chapter II and Chapter III. Analysis of data from the Cancer Registry demonstrated an 
increase in breast cancer incidence after 2006, which corresponds to the timing of the 
implementation of the Medicare Advantage program on the Island. Several questions 
remain to be answered, such as integrating this analysis with elements of clinical 
characteristics of the tumor and staging the cases.  A possible recommendation that can 
be derived from this study is to increase awareness of the importance of evaluating the 
preventive services and treatment received by a breast cancer patient based on the 
tumor's clinical characteristics and staging of the condition as seen by the medical 
provider.  A detailed evaluation of treatment episodes can be suggested as a next step 
complementing the claims-based information with the electronic medical record 







(5,027 cases)  














































































































































































































Figure 4.44 Castellana’s Breast cancer patients by Geographical Region 










































































Figure 48 Breast Cancer Prescriptions per Breast Cancer Case a Year by Drug Category 























































































































































































































































































Figure 49 Overall Injectables Prescriptions per Breast Cancer Cases 

























Mastectomy, modified radical, including axillary
lymph nodes, with or without pectoralis minor
muscle, but excluding pectoralis major muscle
Mastectomy, partial
Mastectomy, partial  with axillary
lymphadenectomy
Mastectomy, partial, with axillary
Mastectomy, radical, including pectoral
muscles, axillary and internal mammary lymph
nodes
Mastectomy, radical, including pectoral






Table 4.1; Diagnostics codes used to identify Breast Cancer Cases from Medical Claims 
ICD9 
Code 
Diagnostic Code Description 
174  
174.0 










Malignant neoplasm of female breast 
Malignant neoplasm of nipple and areola of female breast 
Malignant neoplasm of the central portion of female breast 
Malignant neoplasm of the upper-inner quadrant of female breast 
Malignant neoplasm of the lower-inner quadrant of female breast 
Malignant neoplasm of upper-outer quadrant of female breast 
Malignant neoplasm of the lower-outer quadrant of female breast 
Malignant neoplasm of axillary tail of female breast 
Malignant neoplasm of other specified sites of female breast 
Malignant neoplasm of breast (female), unspecified 
Estrogen receptor-positive status [ER+] 











Patients Age 18 - 44  46 0.92% 
45 - 64  694 13.81% 
65 - 75  2168 43.13% 
76- 84  1452 28.88% 
85+  667 13.27% 
   Frequency Percent 
Geographical Region Central  934 18.58% 
East  819 16.29% 
North  12 0.24% 
Northeast  1,364 27.13% 
North-Metro  660 13.13% 
Northwest  2 0.04% 
San Juan  777 15.46% 
Southeast  400 7.96% 
Southwest  57 1.13% 
West  2 0.04% 
   Frequency Percent 
State-funded Medicaid  Yes  3,233 64.32 
 No  1,794 35.68 
   Frequency Percent 
Specialty Drug ever used Yes  1,536 30.55 







Table 4.3; Percent distribution of Orally Prescribed Drugs to Castellan Medicare 











Table 4.4; Break down of Prescribed Drugs to Castellana Medicare Breast Cancer 
Cases by Drug Class, Subclass, and Drug Names 
 
Drug class Drug subclass Brand 
Alkylating 
Agents Nitrogen Mustards Cyclophosphamide 
Antimetabolites Antimetabolites Methotrexate 
Antineoplastic - 
Hormonal and 
Related Agents Antiestrogens Tamoxifen 
 Aromatase Inhibitors Anastrozole 
  Aromasin 
  Exemestane 
  Femara 
  Letrozole 
 Estrogen Receptor Antagonist Faslodex 
 LHRH Analogs Zoladex 
Antineoplastic 
Enzyme 
Inhibitors Antineoplastic - mTOR Kinase Inhibitors Afinitor 
 
Poly (ADP-ribose) Polymerase (PARP) 
Inhibitors Lynparza 
Mitotic Inhibitors Mitotic Inhibitors Docetaxel 
  Paclitaxel 
  Vinblastine 
  
Drug subclass Frequency Percent 
Aromatase Inhibitors 9,744 73.7% 
Antiestrogens 3,289 24.9% 
Antimetabolites 158 1.2% 





Table 4.5 Percent Distribution for Breast cancer drugs and Drugs Subclass among the 
Castellana’s Breast Cancer Patients 
DRUG 
SUBCLASS 
Afinitor Anastrozole Aromasin Exemestane Femara Letrozole Methotrexate Tamoxifen Total 
Antiestrogens 0 0 0 0 0 0 0 3,289 3,289 
Row% 0% 0% 0% 0% 0% 0% 0% 100% 100% 
Antimetabolites 0 0 0 0 0 0 158 0 158 




24 0 0 0 0 0 0 0 24 
Row% 100% 0% 0% 0% 0% 0% 0% 0% 100% 
Aromatase 
Inhibitors 
0 5,461 642 1,727 618 1,296 - - 9,744 
Row% 0% 56.04% 6.59% 17.72% 6.34% 13.30% 0% 0% 100% 
TOTAL 24 5,461 642 1,727 618 1,296 158 3,289 13,215 
Row% 0.20% 41.30% 4.90% 13.01% 4.70% 9.80% 1.2% 24.9% 100% 






Table 4.6; Injectable Utilization for the Castellana’s Breast Cancer Patients 
 
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Total % 
Office Location 1940 1770 1196 3948 5987 4197 4814 6346 3906 4013 38117 78% 
Cyclophosphamide, 100 mg 12 30 12 30 732 450 696 612 360 648 3582 
 
Goserelin acetate implant, per 3.6 mg 
  
4 16 16 24 8 48 20 32 168 
 
Injection, docetaxel, 1 mg 
   
1100 1875 950 1450 2100 950 975 9400 
 
Injection, paclitaxel protein-bound 




19 7 23 20 7 6 112 
 
Injection, paclitaxel, 1 mg 
        
2398 2244 4642 
 




Injection, vinblastine sulfate, 1 mg 8 10 





Methotrexate sodium, 5 mg 
      
84 42 105 21 252 
 




87 651 663 1936 2393 1196 526 275 
 
7727 16% 
Cyclophosphamide, 100 mg 
    




Goserelin acetate implant, per 3.6 mg 
    
4 
     
4 
 
Injection, docetaxel, 1 mg 
   




Injection, paclitaxel protein-bound 
particles, 1 mg 
    




Injection, paclitaxel, 1 mg 





Injection, paclitaxel, 30 mg 
 




Injection, vinblastine sulfate, 1 mg 










     
84 
 











     
42 3 25 50 
 
120 0% 
Injection, docetaxel, 1 mg 





Injection, paclitaxel, 30 mg 
     
42 
    
42 
 
Methotrexate sodium, 50 mg 
      
3 
   
3 
 
Outpatient hospital 84 231 126 214 229 371 215 441 604 659 3174 6% 
Cyclophosphamide, 100 mg 
    
54 72 78 78 42 114 438 
 
Injection, docetaxel, 1 mg 
   
25 175 275 125 300 150 150 1200 
 
Injection, paclitaxel protein-bound 
particles, 1 mg 
        
29 21 50 
 
Injection, paclitaxel, 1 mg 
        
374 374 748 
 








Methotrexate sodium, 50 mg 
















Table 4.8; Percent Distribution of Service Category of Breast Cancer Cases 
Top Service Class Services % 
Office/other outpatient services 29,004 15.7% 
Drugs Administered Other Than Oral Method, Chemotherapy 
Drugs 24,794 13.4% 
Radiation oncology 22,779 12.3% 
(Hydration, therapeutic, prophylactic, diagnostic injections and 
infusions, and chemotherapy and other highly complex drug or 
highly complex biologic agent administration) 18,346 9.9% 
Hematology and coagulation 12,390 6.7% 
Diagnostic/screening processes or results 11,707 6.3% 
Organ or disease-oriented panels 9,486 5.1% 
Nuclear medicine 2,829 1.5% 
Others 56,892 30% 
 
Table 4.9; Distribution of Services by Medical Service Categories by Year of Service of 
Breast Cancer Cases 
Place of Service 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Office/Other outpatient 
services 3.7 7.5 8.7 10.4 12.7 14.5 17.6 14.3 10.6 
Drugs Administered 
other than Oral 
Methods, 
Chemotherapy 5.2 10.5 6.5 8.0 14.5 13.6 14.9 15.8 11.1 
Radiation Oncology 4.4 13.2 12.2 9.3 12.8 18.7 13.7 10.8 4.9 
Nuclear Medicine 3.4 10.0 10.7 12.5 12.4 14.5 14.5 12.7 9.7 
Chemotherapy 2.9 4.8 7.0 9.3 13.3 15.2 17.5 18.0 12.0 
Hematology and 
coagulation 4.0 8.7 8.3 8.8 13.2 14.7 17.3 14.2 10.8 
 2007 2008 2009 2010 2011 2012 2013 2014 2015 
All medical 
claims 
         
98,473  
       
214,763  
       
240,492  
       
244,689  
       
271,919  
       
298,286  
       
336,336  
       
304,309  




               
1,519  
               
2,062  
               
2,179  
               
2,378  
               
2,702  
               
3,034  
               
3,200  
               
2,839  
               
2,871  
Claims per case                  
64.8  
               
104.2  
               
110.4  
               
102.9  
               
100.6  
                 
98.3  
               
105.1  
               
107.2  






Table 4.10; Distribution of Medical Claims Services by Place of Service 
 











Table 4.11; Percent distribution of Medical Services by Place of Service and Year of Service 
Place of Service 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Office 58% 54% 53% 57% 54% 55% 54% 59% 59% 
Independent 
Laboratory 17% 19% 22% 20% 21% 22% 24% 23% 22% 
On Campus-
Outpatient Hospital 20% 17% 19% 15% 16% 15% 14% 13% 13% 
Home 2% 5% 3% 4% 5% 4% 3% 2% 2% 
Inpatient Hospital 2% 4% 2% 2% 2% 2% 2% 2% 1% 
Ambulance 0% 2% 1% 3% 2% 2% 2% 1% 1% 
Others 0% 0% 0% 1% 0% 0% 0% 0% 0% 





Place of Service Services % 
Office 105,094 56 
Independent Laboratory 40,427 21 
On Campus-Outpatient Hospital 28,477 15 
Home 6,173 3 
Inpatient Hospital 4,047 2 
Ambulance -Land 3,181 2 
Ambulatory Surgical Center 449 0 
Emergency Room - Hospital 158 0 
Custodial Care Facility 70 0 
Mobile Unit 68 0 
Skilled Nursing Facility 3 0 
Urgent Care Facility 1 0 
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This dissertation was undertaken to contribute to the understanding of how breast 
cancer is experienced in Puerto Rico.  During the period of 1987 to the year 2012, an 
increasing number of new cases and a relatively steady mortality rate have been 
observed on the Island. Although a possible decline in mortality may have begun to 
emerge in 2011, this increase in incidence with little change in mortality has occurred 
despite efforts by the government and private sectors to increase access to health 
services for the population and reduce the burden of disease in the Island.    
The second chapter of this thesis described the age-adjusted incidence and 
mortality rates of malignant breast cancer among Puerto Rican women by the Health 
Reform service regions to achieve this goal.  The Health Reform of 1994-2001 was a 
government-led strategy to increase access to services to the medically indigent 
population to reduce health disparities between the public and private healthcare 
sectors.   
To expand on the understating of the disease, the third chapter of this thesis 
addressed these rates in more detail stratifying by clinicians' clinical characteristics to 
allocate treatment to patients.  The elements included tumor grade, histological type, 
and staging of the disease at diagnosis.  The fourth chapter reviewed the services 
received by more than 5,000 women with breast cancer from a large and important 
Medicare Advantage practice in Puerto Rico, the first such analysis of such a database 




The main findings in chapter II were that all Health Reform service regions 
experienced increases in the malignant breast cancer incidence rates from 2000 to 
2013.  The increase was statistically significant in seven out of the ten regions and more 
extensive in the Southeast, East, North, and Central Regions.  The second important 
factor observed in this study was that the incidence rates showed a significant sharp 
increase that began in 2007.    In the year 2007, the Medicare Advantage Program 
became available on the island. The Medicare Advantage Program is federally funded 
and administered by private health insurance companies on the Island. This sharp 
increase in incidence rates might have been the result of the allocation of more funds 
for the elderly population that joined the new Medicare Advantage Program as elderly 
women were now able to receive more and faster referrals to screening, diagnosis, and 
treatment services previously limited to a segment of the population.   
All this activity resulted in more visibility of cases and identification of the disease at 
earlier stages, which was expected to translate into earlier treatment resulting in a 
decrease in mortality.  Improvements in health services access allowed Puerto Rican 
females to receive earlier breast cancer screening, earlier diagnostic testing, and 
access to treatment, which might account for the decrease in breast cancer mortality 
after 2011.  Regions with increases in incidence, such as the Southeast and Southwest 
regions showed slower growth in mortality. These data suggest that government Health 
Reform and the Medicare Advantage Program have increased breast cancer services 
access. Better and faster documentation of new cases in the health service regions 
translates to earlier treatment, reducing early mortality in more aggressive types of 




diagnosis.   The observed increases in the Southeast, East, and Central Region 
suggest that the historical gap in services has been abridged by the new resources 
made available by the state and federal programs now administered by the private 
health insurance companies in those geographical areas. 
Not having the information on the type of health insurance from the cancer registry 
data limited the analysis options for the insurance funding source.  Given that this study 
utilized the State Cancer Registry data, incomplete case ascertainment is a possible 
source of bias as all cases might not be reported to the health providers' registry.  An 
alternative to mitigate this situation would be to complement surveillance efforts with 
new cases reported to health insurance companies, which would complement 
information on cases reported to medical providers' Cancer Registry.  This might also 
help to better document the registry's insurance types, which would enhance the 
analytical options for future studies.  This information is essential for local health and 
state administrators who could use this data to better coordinate prevention efforts in 
the government and private health industry.   
The third chapter evaluated the incidence and mortality rates between 2000 and 
2013 by stage of the disease at diagnosis, histology tumor type, and tumor grades of 
malignant breast cancers. To our knowledge, no recent publication has described 
trends in the distribution of breast cancer cases by clinical characteristics of the disease 
in Puerto Rico.   This chapter's main finding was that the trend analysis showed a sharp 
and significant increase in the incidence among Type III tumors (Invasive, moderately 
metastasizing) for the period.  This increase was higher for infiltrating ductal cell 




Almost 80% of the mortality was attributable to Type III tumors, with nearly 70% 
attributable specifically to infiltrating duct cell carcinomas.  However, the only type that 
presented an increase in the period's mortality rates was the infiltrating ductal cell 
carcinomas. Among Type II histologic tumors (Invasive, circumscribed margins, rare 
metastasis), Mucinous tumors presented a small but significant increase during the 
period.  The remaining types showed either non-significant reductions or stable patterns 
during the period. 
Moderately differentiated tumors were first stable, between 2000 and 2009 and 
presented a sharp and statistically significant increase through the year 2014.  
Malignant breast cases with well-differentiated and poorly differentiated tumors 
increased steadily across the whole period.  In contrast, the incidence of breast cancer 
with undifferentiated tumors decreased.  More aggressive tumors were more frequently 
associated with mortality, with 35% of the breast cancer deaths from “poorly 
differentiated” (Grade 3) tumors.  Less aggressive, “moderately differentiated” (Grade 2) 
tumors represented 31% of the deaths. Given the increases in incidence and mortality 
rates for poorly differentiated tumors (Grade 3), more attention needs to be allocated to 
patients with aggressive tumors, with targeted chemotherapy in the early stages of the 
disease, to help destroy any cancer cells that may have spread as a result of the cancer 
being faster growing. Regarding the disease stage, cases with a regional to lymph node 
stage were initially stable from 2000 to 2009 but followed with a sharp and statistically 
significant increase starting from 2009 to 2014.  Localized tumors like tumors with well 
and poorly differentiated grades showed a constant rise in incidence rates for the whole 




nodes stage increased after 2009, which has been correlated with the increase in the 
use of combined estrogen and progestin hormone replacement therapy in older women, 
which has been documented to increase breast cancer risk.  However, this correlation 
has not been investigated in Puerto Rican women. 
Adjusted incidence and mortality rates were described; however, limited information 
on deaths from 2000-2005 skewed the trend analysis in the early part of the period, 
which might bias the mortality rates.   With this study methodology, we expect that 
describing breast cancer incidence and mortality rates by histological types, grade, and 
staging will become an integrated and systematic section in the reporting for future 
cancer publications in Puerto Rico.   
The fourth chapter's objective was to describe the socio-demographic characteristics 
of a Medicare Advantage breast cancer population in Puerto Rico and analyze the 
utilization of pharmaceutical and medical services for breast cancer treatment during the 
study period. An analysis of the trends and types of treatment helped evaluate if the 
adoption of treatment guidelines improved during this period and identified areas of 
opportunity to improve care.   
The analysis demonstrated an increase in service utilization based on a review of the 
pharmacy claims and medical service claims.  By the end of the study period, more patient 
services were available to the breast cancer population of the Medicare Independent 
Practice Association (IPA) of Primary Care Physicians. Prescriptions per case and 
injectables per case both increased.  The percent receiving aromatase inhibitors also 
increased during the study period.  In contrast, the use of antiestrogens decreased.  A 




for this decrease.  Our prior study of the Puerto Rico Central Cancer Registry identified 
the registry's lack of information on receptor data. These facts raise the question of 
whether providers are not ordering these tests or whether the health plan is not approving 
them, given the lack of evidence for the therapy. 
Among the medical utilization services, we observed increases in treatment in the 
medical provider office setting. Primary care physicians and oncologists attended more 
breast cancer cases, and care and coordination of services were increased by the IPA 
and the study period's health insurance company.  The percentage of utilization among 
independent laboratories also increased, suggesting more access within the system.  In 
contrast, the Outpatient Hospital services' use decreased, which may be a direct effect of 
more patients visiting providers at their office instead of using a hospital setting for 
preventive ambulatory services. One of the specific breast cancer treatment modalities 
evaluated in this study was mastectomy utilization among this population.  The overall 
percentages of partial mastectomies increased during the period, suggesting better 
adoption of treatment guidelines.   
In summary, these data suggest that breast cancer patients' treatment improved 
among female Medicare beneficiaries across the study period, consistent with the findings 
of chapter II and chapter III.  Analysis of data from the Cancer Registry demonstrated an 
increase in breast cancer incidence after 2006, which corresponds to the implementation 
of the Medicare Advantage program on the Island. There are still questions to be 
answered, such as integrating this analysis with elements of clinical characteristics of the 
tumor and staging the cases to evaluate if the services prevented complications and 




is to increase the awareness of the importance of evaluating the preventive services and 
treatment received by a breast cancer patient based on the clinical characteristics of the 
tumor and staging of the condition as seen by the medical provider.  A detailed evaluation 
of the episodes of treatment can be suggested as a next step complementing the claims-
based information with the electronic medical record information for breast cancer 
patients in Puerto Rico 
Taken as a whole, this dissertation does provide for the first time an evaluation of the 
malignant breast cancer incidence and mortality rates by an applied service element 
(Health Reform health services regions), which help understand its effects on the Island.  
Increases in services for the female medical indigent population with breast cancer were 
observed during the study period.  Expanding the typical trend incidence and mortality 
trend analysis in breast cancer to include key clinical prognosis elements such as 
histological type, the grade of the tumor, and the disease stage provides additional 
information to the scientific community to better understand the disease profile in Puerto 
Rico.  Finally, integrating an analysis of breast cancer surveillance with examinations of 
change patterns in treatment regimens using a medical claims database further enhances 
understanding of the incidence and mortality profile. 
We expect that this methodology will be adopted and replicated periodically by the 
Puerto Rico Cancer Registry. Our recommendations include more information on 
additional biomarkers and health insurance types for breast cancer patients within the 
Cancer Registry information.  Also, to Cancer Registry data analysis, breast cancer 
research in the Island must be complemented with studies of breast cancer utilization 




companies.  These data will augment the Registry’s surveillance efforts with electronic 
data on newly identified patients and their procedures and outcomes identified while 
screened or receiving treatment.  These services are billed to the health insurance 
companies daily by medical providers all over the Island. This integrated approach might 
enhance the information's completeness and analytical discussion in the public health 
arena of cancer among researchers and public health officers.    
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